The Lattice (Official 3DHEALS Podcast) Tue, 13 Oct 2026 21:08:18 -0400 https://3dheals.com/ en-us © 2026 3DHEALS LLC yes Support this Podcast 24231022-3fc6-5f62-b12b-c67a45b1baa0 info@3dheals.com 3DHEALS episodic false Welcome to the Lattice podcast, the official podcast for 3DHEALS. This is where you will find fun but in-depth conversations (by founder Jenny Chen) with technological game-changers, creative minds, entrepreneurs, rule-breakers, and more. The conversations focus on using 3D technologies, like 3D printing and bioprinting, AR/VR, and in silico simulation, to reinvent healthcare and life sciences. This podcast will include AMA (Ask Me Anything) sessions, interviews, select past virtual event recordings, and other direct engagements with our Tribe.

While there is no rule for our podcast content, the only rule we follow is to provide our listeners with a maximized return on their attention and time investment.

Follow us on Facebook, Twitter, and Instagram @3dheals, and check out the links in the show notes. 

3DHEALS Links: https://linktr.ee/3dheals



🛑 Disclaimer

The content of this podcast is for informational and educational purposes only and does not constitute medical, legal, or financial advice. The views and opinions expressed by the host and guests are their own and do not necessarily reflect those of their employers, affiliates, or any associated organizations.

While we discuss emerging technologies in healthcare and 3D printing, listeners should consult qualified professionals before making decisions based on the information shared. The mention of specific companies, products, or technologies does not imply endorsement.

This podcast may reference early-stage innovations and concepts that are not yet FDA-approved or commercially available. Always follow regulatory guidelines and ethical standards when applying new technologies in clinical or professional settings.


]]> Buzzsprout (https://www.buzzsprout.com) 3D printing, additive manufacturing, bioprinting, biofabrication, entrepreneurship, dental 3D printing, digital dentistry, advanced materials, technology, Augmented Reality, Virtual Reality 3DHEALS info@3dheals.com https://storage.buzzsprout.com/gi9yxsyvpnq7zoynfjuraa7tljx4?.jpg The Lattice (Official 3DHEALS Podcast) https://3dheals.com/ CNC-Level Micro Metal 3D Printing CNC-Level Micro Metal 3D Printing We talk with Adam Steggi about why minimally invasive medical devices are getting harder to manufacture, and why that manufacturing constraint now shapes what products can exist at all. Adam shares how Trail Labs built Ripple to deliver CNC-equivalent micro metal parts in stainless steel, then chose a parts-first business model to drive real adoption.  
00:00:00 - Welcome And A Parts-First Thesis
00:01:20 - Founder Lessons From A First Startup
00:04:45 - Minimally Invasive Devices Hit Manufacturing Limits
00:09:36 - Why RILP Had To Be Invented
00:11:48 - Selling Parts Instead Of Printers
00:17:06 - RIPL Explained And Where It Wins
00:19:58 - Finding Customers And Building To Production
00:22:50 - Unit Economics Versus CNC And MIM
00:27:19 - Scaling Challenges And The 2027 Goal
00:29:50 - Disclaimer And Closing

Send us Fan Mail

Support the show

Subscribe to our premium version and support the show. 

Follow us:
Twitter 
Instagram
Linkedin
3DHEALS Website
Facebook
Facebook Group
Youtube channel

About Pitch3D 

]]> We talk with Adam Steggi about why minimally invasive medical devices are getting harder to manufacture, and why that manufacturing constraint now shapes what products can exist at all. Adam shares how Trail Labs built Ripple to deliver CNC-equivalent micro metal parts in stainless steel, then chose a parts-first business model to drive real adoption.  
00:00:00 - Welcome And A Parts-First Thesis
00:01:20 - Founder Lessons From A First Startup
00:04:45 - Minimally Invasive Devices Hit Manufacturing Limits
00:09:36 - Why RILP Had To Be Invented
00:11:48 - Selling Parts Instead Of Printers
00:17:06 - RIPL Explained And Where It Wins
00:19:58 - Finding Customers And Building To Production
00:22:50 - Unit Economics Versus CNC And MIM
00:27:19 - Scaling Challenges And The 2027 Goal
00:29:50 - Disclaimer And Closing

Send us Fan Mail

Support the show

Subscribe to our premium version and support the show. 

Follow us:
Twitter 
Instagram
Linkedin
3DHEALS Website
Facebook
Facebook Group
Youtube channel

About Pitch3D 

]]> 3DHEALS Buzzsprout-19957549 Tue, 13 Oct 2026 18:00:00 -0400 1811 130 full false Episode #129 | Additive Manufacturing Needs Policy To Reach Patients with Dr. Naomi Nathan Episode #129 | Additive Manufacturing Needs Policy To Reach Patients with Dr. Naomi Nathan Healthcare loves innovation right up until the bill shows up. We sit down with Dr. Nayumi Nathan (Naomi), a medical doctor turned public health and health economics leader, to unpack why medical 3D printing and additive manufacturing are often ready before the healthcare system is. If you’ve ever wondered why point-of-care 3D printing can thrive in one hospital and stall in another, the answer is usually not the printer. It is reimbursement, evidence, and policy.

We dig into how Mobility Goes Additive (MGA) builds a Europe-wide ecosystem that connects hospitals, MedTech companies, researchers, regulators, and industry partners to move from scattered pilots to real adoption. Naomi explains why the EU is uniquely complex for healthcare market access: health authority is national, so scaling custom medical devices, patient-specific implants, and hospital 3D printing programs means navigating 26+ reimbursement and governance environments. That reality changes how startups and scale-ups should plan timelines, partnerships, and investment needs.

The conversation gets concrete on what must happen next: registries, multi-center studies, and credible patient outcome data that can support evidence-based policy and sustainable payment models. We also talk advocacy, political champions, and why additive manufacturing needs “commitment followed by investment,” including scale-up funding, not just startup grants. Along the way, we reality-check bioprinting hype and share what it will take for patients to one day ask for a 3D printed knee like it’s normal.

If you care about the future of medical 3D printing in Europe and beyond, listen, subscribe, and share this with someone building in healthcare. After you listen, leave a review and tell us: what is the biggest barrier to adoption where you live?


YouTube: coming soon

Show notes: coming soon

Send us Fan Mail

Support the show

Subscribe to our premium version and support the show. 

Follow us:
Twitter 
Instagram
Linkedin
3DHEALS Website
Facebook
Facebook Group
Youtube channel

About Pitch3D 

]]> Healthcare loves innovation right up until the bill shows up. We sit down with Dr. Nayumi Nathan (Naomi), a medical doctor turned public health and health economics leader, to unpack why medical 3D printing and additive manufacturing are often ready before the healthcare system is. If you’ve ever wondered why point-of-care 3D printing can thrive in one hospital and stall in another, the answer is usually not the printer. It is reimbursement, evidence, and policy.

We dig into how Mobility Goes Additive (MGA) builds a Europe-wide ecosystem that connects hospitals, MedTech companies, researchers, regulators, and industry partners to move from scattered pilots to real adoption. Naomi explains why the EU is uniquely complex for healthcare market access: health authority is national, so scaling custom medical devices, patient-specific implants, and hospital 3D printing programs means navigating 26+ reimbursement and governance environments. That reality changes how startups and scale-ups should plan timelines, partnerships, and investment needs.

The conversation gets concrete on what must happen next: registries, multi-center studies, and credible patient outcome data that can support evidence-based policy and sustainable payment models. We also talk advocacy, political champions, and why additive manufacturing needs “commitment followed by investment,” including scale-up funding, not just startup grants. Along the way, we reality-check bioprinting hype and share what it will take for patients to one day ask for a 3D printed knee like it’s normal.

If you care about the future of medical 3D printing in Europe and beyond, listen, subscribe, and share this with someone building in healthcare. After you listen, leave a review and tell us: what is the biggest barrier to adoption where you live?


YouTube: coming soon

Show notes: coming soon

Send us Fan Mail

Support the show

Subscribe to our premium version and support the show. 

Follow us:
Twitter 
Instagram
Linkedin
3DHEALS Website
Facebook
Facebook Group
Youtube channel

About Pitch3D 

]]> 3DHEALS Buzzsprout-19896111 Thu, 01 Oct 2026 15:00:00 -0400 2594 129 full false Episode #128 | Biotools Can Beat Moonshots with Jim West Episode #128 | Biotools Can Beat Moonshots with Jim West Everyone wants to fund the next miracle drug. Jim West thinks differently. In this episode, the Associate Director of BioTools Innovator makes the case that life-science tools and diagnostics are the better risk-adjusted venture bet than many therapeutics: you trade the 100X biotech moonshot for a 5-to-10X return with better odds, little regulatory risk, and a roughly five-year horizon. He backs it with the accelerator's own numbers: 95% of the companies through its six cohorts are still operating or acquired, out of roughly 2,800 applications — and explains why focus (not technology) is what most tool founders get wrong, what strategic acquirers actually pay for, and why private equity and family offices are reshaping how these companies get funded.

Show notes

YouTube Recording

Send us Fan Mail

Support the show

Subscribe to our premium version and support the show. 

Follow us:
Twitter 
Instagram
Linkedin
3DHEALS Website
Facebook
Facebook Group
Youtube channel

About Pitch3D 

]]> Everyone wants to fund the next miracle drug. Jim West thinks differently. In this episode, the Associate Director of BioTools Innovator makes the case that life-science tools and diagnostics are the better risk-adjusted venture bet than many therapeutics: you trade the 100X biotech moonshot for a 5-to-10X return with better odds, little regulatory risk, and a roughly five-year horizon. He backs it with the accelerator's own numbers: 95% of the companies through its six cohorts are still operating or acquired, out of roughly 2,800 applications — and explains why focus (not technology) is what most tool founders get wrong, what strategic acquirers actually pay for, and why private equity and family offices are reshaping how these companies get funded.

Show notes

YouTube Recording

Send us Fan Mail

Support the show

Subscribe to our premium version and support the show. 

Follow us:
Twitter 
Instagram
Linkedin
3DHEALS Website
Facebook
Facebook Group
Youtube channel

About Pitch3D 

]]> 3DHEALS Buzzsprout-19871080 Sun, 27 Sep 2026 16:00:00 -0400 1548 128 full false Episode#127 | Lean Compliance For Medical 3D Printing With Erik Boelen Episode#127 | Lean Compliance For Medical 3D Printing With Erik Boelen We talk with Erik Boelen, founder of Qase3D, about how medical 3D printing went from a regulatory free-for-all to a world where hospital print labs function as medical device manufacturers. We break down MDR, CE marking, ISO 13485, and how to stay compliant with a lean system engineers will actually use. 
• The early “no rules” era and why proof of quality becomes unavoidable 
• How MDR and CE marking work for standard medical devices 
• Why custom-made devices can be CE-exempt yet still heavily regulated 
• ISO 13485 as a process-focused QMS and where it helps most 
• Building a lean, day-to-day QMS instead of a paperwork vault 
• The MDR Portal approach and the value of lawyer-backed interpretation 
• Practical triggers for when a growing lab should consider ISO 13485 certification  

00:00:00 - Welcome To The Regulatory Reality
00:03:10 - MDR, CE Mark, And ISO 13485
00:06:30 - Making Implants Before Clear Rules
00:08:33 - What Custom Made Really Means
00:10:20 - From Engineer To Quality Builder
00:12:12 - A Lean QMS People Actually Use
00:17:33 - The MDR Portal And Lawyer Support
00:26:45 - Scaling Compliance Without Bureaucracy
00:30:40 - The Future Of Hospital 3D Labs
00:41:05 - How To Contact Erik
00:43:15 - Disclaimer

Show notes: https://3dheals.com/episode-127-lean-compliance-for-medical-3d-printing-with-erik-boelen/

YouTube: https://youtu.be/wR7TVN4WGno?si=pvQ-Fl7VJNgNRq7F


Send us Fan Mail

Support the show

Subscribe to our premium version and support the show. 

Follow us:
Twitter 
Instagram
Linkedin
3DHEALS Website
Facebook
Facebook Group
Youtube channel

About Pitch3D 

]]> We talk with Erik Boelen, founder of Qase3D, about how medical 3D printing went from a regulatory free-for-all to a world where hospital print labs function as medical device manufacturers. We break down MDR, CE marking, ISO 13485, and how to stay compliant with a lean system engineers will actually use. 
• The early “no rules” era and why proof of quality becomes unavoidable 
• How MDR and CE marking work for standard medical devices 
• Why custom-made devices can be CE-exempt yet still heavily regulated 
• ISO 13485 as a process-focused QMS and where it helps most 
• Building a lean, day-to-day QMS instead of a paperwork vault 
• The MDR Portal approach and the value of lawyer-backed interpretation 
• Practical triggers for when a growing lab should consider ISO 13485 certification  

00:00:00 - Welcome To The Regulatory Reality
00:03:10 - MDR, CE Mark, And ISO 13485
00:06:30 - Making Implants Before Clear Rules
00:08:33 - What Custom Made Really Means
00:10:20 - From Engineer To Quality Builder
00:12:12 - A Lean QMS People Actually Use
00:17:33 - The MDR Portal And Lawyer Support
00:26:45 - Scaling Compliance Without Bureaucracy
00:30:40 - The Future Of Hospital 3D Labs
00:41:05 - How To Contact Erik
00:43:15 - Disclaimer

Show notes: https://3dheals.com/episode-127-lean-compliance-for-medical-3d-printing-with-erik-boelen/

YouTube: https://youtu.be/wR7TVN4WGno?si=pvQ-Fl7VJNgNRq7F


Send us Fan Mail

Support the show

Subscribe to our premium version and support the show. 

Follow us:
Twitter 
Instagram
Linkedin
3DHEALS Website
Facebook
Facebook Group
Youtube channel

About Pitch3D 

]]> 3DHEALS Buzzsprout-19823130 Thu, 17 Sep 2026 14:00:00 -0400 2616 full false Episode#126| Biomaterials Frontier for Medical 3D Printing (Virtual Event Recording) Episode#126| Biomaterials Frontier for Medical 3D Printing (Virtual Event Recording) The real frontier in medical 3D printing isn't the printer — it's the material. In this 3DHEALS panel, five researchers, founders, and industry leaders map the shift from printing structure to printing function, and from lab-stage novelty toward regulated, investment-grade material systems spanning soft bioresins, bioactive ceramics, and titanium lattices.

Fabian Trumper (Arrakis Bio) argues that the best biomaterials are the ones our bodies already make, and explains how his team bio-manufactures True Human Collagen at industrial scale. Prof. Kamal Choudhary (Johns Hopkins) shows why AI is reshaping materials discovery — a "ChatGPT for materials scientists" — and why so much of the field still isn't reproducible. Dr. Andrew Weems (Resilient Medical) shares how a 3D-printed scaffold could finally modernize lumpectomy surgery for breast cancer patients. Ebrahim Yarali (MERLN, Maastricht University) reveals how geometry alone — architected "meta-biomaterials" and 4D printing — can steer stem cells toward bone or cartilage. And Dr. Scott Taylor (Poly-Med) breaks down absorbable polymers that dissolve into the body once healing is done. Moderated by Craig Rosenblum, President of Himed.

In this episode:

  • Human vs. synthetic biomaterials — and what cells actually "notice"
  • AI-designed materials and the reproducibility crisis
  • Designing devices for the surgery we already do
  • 4D printing and geometry as a biological signal
  • A live debate: can AI and lab models replace animal testing?

Whether you're a researcher, founder, or investor, this is a fast, opinionated tour of where medical materials are heading next.

🎥 Watch the full session and explore more 3DHEALS events: https://3dheals.com/biomaterials-frontier/

00:00:00 - Welcome And 3D Heals Missions
00:01:58 - Event Setup And Sponsor Context
00:04:08 - Absorbable Polymers And Degradation Design
00:10:07 - Pore Size And Surface Area Effects
00:12:40 - True Human Collagen For Regeneration
00:23:08 - Collagen Q&A On Regulation
00:28:58 - AI Tools For Materials Discovery
00:41:35 - AI Limits Data And Loop Closure
00:50:31 - Lumpectomy Scaffolds And Go To Market
01:01:47 - Academia Versus Startup Mindset
01:10:13 - Geometry Driven Bone Regeneration Scaffolds
01:24:11 - Acoustic Responsive And 4D Biomaterials
01:31:08 - Panel Debate On Animal Testing
01:37:39 - AI Hype Real Impact And Wish List
01:46:51 - Final Takeaways And Closing

Send us Fan Mail

Support the show

Subscribe to our premium version and support the show. 

Follow us:
Twitter 
Instagram
Linkedin
3DHEALS Website
Facebook
Facebook Group
Youtube channel

About Pitch3D 

]]> The real frontier in medical 3D printing isn't the printer — it's the material. In this 3DHEALS panel, five researchers, founders, and industry leaders map the shift from printing structure to printing function, and from lab-stage novelty toward regulated, investment-grade material systems spanning soft bioresins, bioactive ceramics, and titanium lattices.

Fabian Trumper (Arrakis Bio) argues that the best biomaterials are the ones our bodies already make, and explains how his team bio-manufactures True Human Collagen at industrial scale. Prof. Kamal Choudhary (Johns Hopkins) shows why AI is reshaping materials discovery — a "ChatGPT for materials scientists" — and why so much of the field still isn't reproducible. Dr. Andrew Weems (Resilient Medical) shares how a 3D-printed scaffold could finally modernize lumpectomy surgery for breast cancer patients. Ebrahim Yarali (MERLN, Maastricht University) reveals how geometry alone — architected "meta-biomaterials" and 4D printing — can steer stem cells toward bone or cartilage. And Dr. Scott Taylor (Poly-Med) breaks down absorbable polymers that dissolve into the body once healing is done. Moderated by Craig Rosenblum, President of Himed.

In this episode:

  • Human vs. synthetic biomaterials — and what cells actually "notice"
  • AI-designed materials and the reproducibility crisis
  • Designing devices for the surgery we already do
  • 4D printing and geometry as a biological signal
  • A live debate: can AI and lab models replace animal testing?

Whether you're a researcher, founder, or investor, this is a fast, opinionated tour of where medical materials are heading next.

🎥 Watch the full session and explore more 3DHEALS events: https://3dheals.com/biomaterials-frontier/

00:00:00 - Welcome And 3D Heals Missions
00:01:58 - Event Setup And Sponsor Context
00:04:08 - Absorbable Polymers And Degradation Design
00:10:07 - Pore Size And Surface Area Effects
00:12:40 - True Human Collagen For Regeneration
00:23:08 - Collagen Q&A On Regulation
00:28:58 - AI Tools For Materials Discovery
00:41:35 - AI Limits Data And Loop Closure
00:50:31 - Lumpectomy Scaffolds And Go To Market
01:01:47 - Academia Versus Startup Mindset
01:10:13 - Geometry Driven Bone Regeneration Scaffolds
01:24:11 - Acoustic Responsive And 4D Biomaterials
01:31:08 - Panel Debate On Animal Testing
01:37:39 - AI Hype Real Impact And Wish List
01:46:51 - Final Takeaways And Closing

Send us Fan Mail

Support the show

Subscribe to our premium version and support the show. 

Follow us:
Twitter 
Instagram
Linkedin
3DHEALS Website
Facebook
Facebook Group
Youtube channel

About Pitch3D 

]]> 3DHEALS Buzzsprout-19799821 Sun, 13 Sep 2026 22:00:00 -0400 6428 126 full false Episode 125| Inside Tech Transfer At UCLA From Patents To Patients Episode 125| Inside Tech Transfer At UCLA From Patents To Patients A single university discovery can turn into a life-changing therapy, but only if someone can translate the science into a product, a company, and a development plan investors will actually fund. That is why we sat down with Mark from UCLA’s technology transfer and licensing team to demystify what happens after the lab result and before the biotech headline. We talk plainly about what a tech transfer office does, what it can license, and why “intellectual property” now stretches beyond patents into data, materials, and even carefully governed patient datasets.

We also zoom out to the policy foundation that made modern university commercialization possible: the Bayh-Dole Act. Mark explains how shifting IP ownership from the federal government to universities changed licensing outcomes and helped build the innovation ecosystem we now associate with US leadership in therapeutics. Along the way, we connect the dots to real UCLA impact, including major prostate cancer drugs and a licensed cure for ADA-SCID, and we unpack the tension founders often feel when a faculty inventor becomes a startup founder negotiating with their own campus.

Then we get tactical. We break down why big pharma often waits until risk is reduced, why faculty-led startups become the bridge, and how license strategy changes depending on whether you are building a therapeutic that needs exclusivity or a platform that benefits from nonexclusive access. Mark walks through diligence milestones, annual progress reporting, and the practical reality that most “shelving” is not malicious, it is a startup fighting for survival. If you care about biotech startups, university patents, and the future of the Los Angeles bioscience ecosystem, this conversation is a roadmap.

If this helped you see tech transfer differently, subscribe, share the episode with a founder or researcher, and leave a review telling us what part of the university-to-startup journey you want us to unpack next.


Show notes: coming soon

YouTube: coming soon

Send us Fan Mail

Support the show

Subscribe to our premium version and support the show. 

Follow us:
Twitter 
Instagram
Linkedin
3DHEALS Website
Facebook
Facebook Group
Youtube channel

About Pitch3D 

]]> A single university discovery can turn into a life-changing therapy, but only if someone can translate the science into a product, a company, and a development plan investors will actually fund. That is why we sat down with Mark from UCLA’s technology transfer and licensing team to demystify what happens after the lab result and before the biotech headline. We talk plainly about what a tech transfer office does, what it can license, and why “intellectual property” now stretches beyond patents into data, materials, and even carefully governed patient datasets.

We also zoom out to the policy foundation that made modern university commercialization possible: the Bayh-Dole Act. Mark explains how shifting IP ownership from the federal government to universities changed licensing outcomes and helped build the innovation ecosystem we now associate with US leadership in therapeutics. Along the way, we connect the dots to real UCLA impact, including major prostate cancer drugs and a licensed cure for ADA-SCID, and we unpack the tension founders often feel when a faculty inventor becomes a startup founder negotiating with their own campus.

Then we get tactical. We break down why big pharma often waits until risk is reduced, why faculty-led startups become the bridge, and how license strategy changes depending on whether you are building a therapeutic that needs exclusivity or a platform that benefits from nonexclusive access. Mark walks through diligence milestones, annual progress reporting, and the practical reality that most “shelving” is not malicious, it is a startup fighting for survival. If you care about biotech startups, university patents, and the future of the Los Angeles bioscience ecosystem, this conversation is a roadmap.

If this helped you see tech transfer differently, subscribe, share the episode with a founder or researcher, and leave a review telling us what part of the university-to-startup journey you want us to unpack next.


Show notes: coming soon

YouTube: coming soon

Send us Fan Mail

Support the show

Subscribe to our premium version and support the show. 

Follow us:
Twitter 
Instagram
Linkedin
3DHEALS Website
Facebook
Facebook Group
Youtube channel

About Pitch3D 

]]> 3DHEALS Buzzsprout-19752129 Thu, 03 Sep 2026 19:00:00 -0400 2568 125 full false Episode#123| Bioprinting In Microgravity with Dr. Michael Roberts ISS/CASIS Episode#123| Bioprinting In Microgravity with Dr. Michael Roberts ISS/CASIS Gravity shapes every lab workflow we take for granted, and it may be the hidden constraint behind some of the hardest problems in regenerative medicine. We sit down with Dr. Michael Roberts, a microecologist who led bioregenerative life support research at NASA’s Kennedy Space Center and now serves as Chief Scientific Officer of the International Space Station National Laboratory, to talk about what microgravity is actually good for and why biomanufacturing in space is no longer just sci-fi.

YouTube: Pending

Show notes: Pending

Send us Fan Mail

Support the show

Subscribe to our premium version and support the show. 

Follow us:
Twitter 
Instagram
Linkedin
3DHEALS Website
Facebook
Facebook Group
Youtube channel

About Pitch3D 

]]> Gravity shapes every lab workflow we take for granted, and it may be the hidden constraint behind some of the hardest problems in regenerative medicine. We sit down with Dr. Michael Roberts, a microecologist who led bioregenerative life support research at NASA’s Kennedy Space Center and now serves as Chief Scientific Officer of the International Space Station National Laboratory, to talk about what microgravity is actually good for and why biomanufacturing in space is no longer just sci-fi.

YouTube: Pending

Show notes: Pending

Send us Fan Mail

Support the show

Subscribe to our premium version and support the show. 

Follow us:
Twitter 
Instagram
Linkedin
3DHEALS Website
Facebook
Facebook Group
Youtube channel

About Pitch3D 

]]> 3DHEALS Buzzsprout-19678593 Thu, 20 Aug 2026 17:00:00 -0400 3419 123 full false Episode #122| The Mini Brain That Learned Pac-Man: NAMs with Dr. Lowry Curley Episode #122| The Mini Brain That Learned Pac-Man: NAMs with Dr. Lowry Curley A brain organoid that can learn to play Pac-Man sounds like a stunt until you realize what it represents: measurable learning, rewiring, and human-relevant neural function that animal models often fail to predict. We talk with Dr. Lowry Curley, founder of Luna LifeSci and former CEO and co-founder of Axosim (now 28 Bio), about why neuroscience drug development breaks so often and how NAMs are finally giving teams better tools to make safer calls earlier.

If you’re building in biotech, investing in drug discovery, or just trying to understand what replaces animal testing next, this conversation gives you a clear map of the technology, the incentives, and the milestones to watch. Subscribe, share this with a colleague, and leave a review with the biggest NAM question you want answered next.

Show notes: https://3dheals.com/episode-122-new-approach-methodologies-nams-with-dr-lowry-curley/

YouTube: https://youtu.be/suVxiYZgPVE

Send us Fan Mail

Support the show

Subscribe to our premium version and support the show. 

Follow us:
Twitter 
Instagram
Linkedin
3DHEALS Website
Facebook
Facebook Group
Youtube channel

About Pitch3D 

]]> A brain organoid that can learn to play Pac-Man sounds like a stunt until you realize what it represents: measurable learning, rewiring, and human-relevant neural function that animal models often fail to predict. We talk with Dr. Lowry Curley, founder of Luna LifeSci and former CEO and co-founder of Axosim (now 28 Bio), about why neuroscience drug development breaks so often and how NAMs are finally giving teams better tools to make safer calls earlier.

If you’re building in biotech, investing in drug discovery, or just trying to understand what replaces animal testing next, this conversation gives you a clear map of the technology, the incentives, and the milestones to watch. Subscribe, share this with a colleague, and leave a review with the biggest NAM question you want answered next.

Show notes: https://3dheals.com/episode-122-new-approach-methodologies-nams-with-dr-lowry-curley/

YouTube: https://youtu.be/suVxiYZgPVE

Send us Fan Mail

Support the show

Subscribe to our premium version and support the show. 

Follow us:
Twitter 
Instagram
Linkedin
3DHEALS Website
Facebook
Facebook Group
Youtube channel

About Pitch3D 

]]> 3DHEALS Buzzsprout-19615936 Fri, 07 Aug 2026 18:00:00 -0400 2973 122 full false Episode #121| Absorbable Biomaterials with Dr. Rao Bezwada Episode #121| Absorbable Biomaterials with Dr. Rao Bezwada Absorbable biomaterials have transformed modern medicine, enabling implants, sutures, and drug-delivery systems that safely degrade once their function is complete. Dr. Rao S. Bezwada has helped shape the field of bioresorbable polymers for more than three decades. As the inventor of Monocryl®, the absorbable suture that has generated more than $2 billion in worldwide sales, and the holder of more than 150 U.S. patents, his innovations have influenced everything from surgical sutures to next-generation biomaterials. In this episode of The Lattice, Dr. Bezwada joins Dr. Jenny Chen to discuss the science behind bioresorbable polymers, the chemistry that controls how materials degrade, and what the next generation of resorbable biomaterials could make possible.


⚠️ Disclaimer:
This podcast is for educational and informational purposes only. The views expressed do not constitute engineering, medical, or financial advice. The technologies and procedures discussed may not be commercially available or suitable for every case. Always consult with a qualified professional.


YouTube video: 

Show notes: https://3dheals.com/episode-121-absorbable-biomaterials-with-dr-rao-bezwada/

Send us Fan Mail

Support the show

Subscribe to our premium version and support the show. 

Follow us:
Twitter 
Instagram
Linkedin
3DHEALS Website
Facebook
Facebook Group
Youtube channel

About Pitch3D 

]]> Absorbable biomaterials have transformed modern medicine, enabling implants, sutures, and drug-delivery systems that safely degrade once their function is complete. Dr. Rao S. Bezwada has helped shape the field of bioresorbable polymers for more than three decades. As the inventor of Monocryl®, the absorbable suture that has generated more than $2 billion in worldwide sales, and the holder of more than 150 U.S. patents, his innovations have influenced everything from surgical sutures to next-generation biomaterials. In this episode of The Lattice, Dr. Bezwada joins Dr. Jenny Chen to discuss the science behind bioresorbable polymers, the chemistry that controls how materials degrade, and what the next generation of resorbable biomaterials could make possible.


⚠️ Disclaimer:
This podcast is for educational and informational purposes only. The views expressed do not constitute engineering, medical, or financial advice. The technologies and procedures discussed may not be commercially available or suitable for every case. Always consult with a qualified professional.


YouTube video: 

Show notes: https://3dheals.com/episode-121-absorbable-biomaterials-with-dr-rao-bezwada/

Send us Fan Mail

Support the show

Subscribe to our premium version and support the show. 

Follow us:
Twitter 
Instagram
Linkedin
3DHEALS Website
Facebook
Facebook Group
Youtube channel

About Pitch3D 

]]> 3DHEALS Buzzsprout-19577180 Thu, 30 Jul 2026 16:00:00 -0400 3100 121 full false Episode #119 | 3D Printing At The Dentist with Dr. Nabeel Cajee Episode #119 | 3D Printing At The Dentist with Dr. Nabeel Cajee If you have ever wondered why dentistry can feel both high-tech and oddly hand-built at the same time, this conversation connects the dots. We talk with Dr. Nabeel Cajee, an oral implantologist in Newport Beach and faculty at Torque Academy and Implant Ninja School, about what it really takes to bring digital dentistry into daily patient care without turning your practice into a science project. From the earliest days of open-source 3D printing to today’s clinical workflows, he breaks the ecosystem down into what actually matters: data capture, dental CAD design, and fabrication with dependable post-processing.

If you care about dental 3D printing, chairside CAD/CAM, guided implant surgery, or the future of restorative dentistry, subscribe, share this with a colleague, and leave a review with your biggest question about digital workflows.


Show notes: https://3dheals.com/episode-119-where-is-dental-3d-printing-with-dr-nabeel-cajee/

YouTube Video: https://youtu.be/FOKQNpMJjb4?si=DImMXMXEiNH5oheH

Send us Fan Mail

Support the show

Subscribe to our premium version and support the show. 

Follow us:
Twitter 
Instagram
Linkedin
3DHEALS Website
Facebook
Facebook Group
Youtube channel

About Pitch3D 

]]> If you have ever wondered why dentistry can feel both high-tech and oddly hand-built at the same time, this conversation connects the dots. We talk with Dr. Nabeel Cajee, an oral implantologist in Newport Beach and faculty at Torque Academy and Implant Ninja School, about what it really takes to bring digital dentistry into daily patient care without turning your practice into a science project. From the earliest days of open-source 3D printing to today’s clinical workflows, he breaks the ecosystem down into what actually matters: data capture, dental CAD design, and fabrication with dependable post-processing.

If you care about dental 3D printing, chairside CAD/CAM, guided implant surgery, or the future of restorative dentistry, subscribe, share this with a colleague, and leave a review with your biggest question about digital workflows.


Show notes: https://3dheals.com/episode-119-where-is-dental-3d-printing-with-dr-nabeel-cajee/

YouTube Video: https://youtu.be/FOKQNpMJjb4?si=DImMXMXEiNH5oheH

Send us Fan Mail

Support the show

Subscribe to our premium version and support the show. 

Follow us:
Twitter 
Instagram
Linkedin
3DHEALS Website
Facebook
Facebook Group
Youtube channel

About Pitch3D 

]]> 3DHEALS Buzzsprout-19506202 Thu, 16 Jul 2026 19:00:00 -0400 2995 119 full false Episode#117| Monica Wellejus:The Road to 3D-Printed Bone Episode#117| Monica Wellejus:The Road to 3D-Printed Bone Ossiform is on track to bring the first 3D printed resorbable bone implant to the US market. The company’s preclinical data showed full bone regeneration in six months. Monica Wellejus, Chief Commercial Officer of Ossiform, joins The Lattice to explain how a company built to personalize bone implants for craniomaxillofacial surgeries is pivoting to mass-produced bone implants for foot deformity, and why hospital finance teams, not just the surgeons, may decide whether this technology actually reaches patients.
⚠️ Disclaimer:
This podcast is for educational and informational purposes only. The views expressed do not constitute engineering, medical, or financial advice. The technologies and procedures discussed may not be commercially available or suitable for every case. Always consult with a qualified professional
00:00 Intro | Why 3D printed bone has not reached patients yet

02:08 Meet Monica Wellejus and Ossiform

05:41 How Ossiform prints bone substitutes using β-TCP ceramics

10:12 The long road to FDA clearance and U.S. market entry

14:03 Why Ossiform moved away from personalized implants

18:26 Listening to surgeons changed everything

23:47 Flatfoot reconstruction and Ossiform’s first clinical products

30:18 Fundraising, commercialization, and building a MedTech startup

38: 54 The hidden decision-makers in healthcare adoption

46:31 The future of bone regeneration, AI, and point-of-care manufacturing


Show notes: https://3dheals.com/episode-117-monica-wellejus-the-road-to-3d-printed-bone/
YouTube link:  https://youtu.be/E8t35WzV7Eg?si=QH-XHfJDwihvqv6n

Send us Fan Mail

Support the show

Subscribe to our premium version and support the show. 

Follow us:
Twitter 
Instagram
Linkedin
3DHEALS Website
Facebook
Facebook Group
Youtube channel

About Pitch3D 

]]> Ossiform is on track to bring the first 3D printed resorbable bone implant to the US market. The company’s preclinical data showed full bone regeneration in six months. Monica Wellejus, Chief Commercial Officer of Ossiform, joins The Lattice to explain how a company built to personalize bone implants for craniomaxillofacial surgeries is pivoting to mass-produced bone implants for foot deformity, and why hospital finance teams, not just the surgeons, may decide whether this technology actually reaches patients.
⚠️ Disclaimer:
This podcast is for educational and informational purposes only. The views expressed do not constitute engineering, medical, or financial advice. The technologies and procedures discussed may not be commercially available or suitable for every case. Always consult with a qualified professional
00:00 Intro | Why 3D printed bone has not reached patients yet

02:08 Meet Monica Wellejus and Ossiform

05:41 How Ossiform prints bone substitutes using β-TCP ceramics

10:12 The long road to FDA clearance and U.S. market entry

14:03 Why Ossiform moved away from personalized implants

18:26 Listening to surgeons changed everything

23:47 Flatfoot reconstruction and Ossiform’s first clinical products

30:18 Fundraising, commercialization, and building a MedTech startup

38: 54 The hidden decision-makers in healthcare adoption

46:31 The future of bone regeneration, AI, and point-of-care manufacturing


Show notes: https://3dheals.com/episode-117-monica-wellejus-the-road-to-3d-printed-bone/
YouTube link:  https://youtu.be/E8t35WzV7Eg?si=QH-XHfJDwihvqv6n

Send us Fan Mail

Support the show

Subscribe to our premium version and support the show. 

Follow us:
Twitter 
Instagram
Linkedin
3DHEALS Website
Facebook
Facebook Group
Youtube channel

About Pitch3D 

]]> 3DHEALS Buzzsprout-19376799 Sat, 20 Jun 2026 21:00:00 -0400 2637 117 full false Episode #115| Professor Paul Dalton: Inventing Melt Electrowriting and the Future of Biofabricationrication Episode #115| Professor Paul Dalton: Inventing Melt Electrowriting and the Future of Biofabricationrication What does it take to invent a technology that didn't exist before?

In this episode, host Dr. Jenny Chen sits down with Professor Paul Dalton, the inventor of melt electrowriting (MEW) and one of the rare "triple threats" in science: an inventor, educator, and futurist. This is also a conversation about science, creativity, and why MEW isn't just a technology but a movement.

Paul takes us from a boredom-filled childhood on a rural farm outside Perth, Australia, to the ophthalmic research lab where he helped build artificial corneas that restored sight to blind patients. He shares the moment a failing electrospinning experiment pushed him toward MEW instead — and the "breathless" discovery under the microscope that became MEW.

Along the way, Jenny and Paul explore:

  • What electrospinning and melt electrowriting actually are, explained in plain language
  • Why MEW pulls fibers instead of pushing them, and how it prints at one-tenth of a teardrop per hour
  • The decades-long pursuit of clinical applications
  • The open-source "MEWron" printer is bringing MEW to labs for a fraction of the cost of commercial machines
  • The two kinds of makers — builders vs. users — and where the community is heading
  • Paul's advice for clinicians and newcomers entering biofabrication

Plus, a remarkable offer for listeners at the end of this episode. 

đź”— Show notes

YouTube recording: Coming soon

Send us Fan Mail

Support the show

Subscribe to our premium version and support the show. 

Follow us:
Twitter 
Instagram
Linkedin
3DHEALS Website
Facebook
Facebook Group
Youtube channel

About Pitch3D 

]]> What does it take to invent a technology that didn't exist before?

In this episode, host Dr. Jenny Chen sits down with Professor Paul Dalton, the inventor of melt electrowriting (MEW) and one of the rare "triple threats" in science: an inventor, educator, and futurist. This is also a conversation about science, creativity, and why MEW isn't just a technology but a movement.

Paul takes us from a boredom-filled childhood on a rural farm outside Perth, Australia, to the ophthalmic research lab where he helped build artificial corneas that restored sight to blind patients. He shares the moment a failing electrospinning experiment pushed him toward MEW instead — and the "breathless" discovery under the microscope that became MEW.

Along the way, Jenny and Paul explore:

  • What electrospinning and melt electrowriting actually are, explained in plain language
  • Why MEW pulls fibers instead of pushing them, and how it prints at one-tenth of a teardrop per hour
  • The decades-long pursuit of clinical applications
  • The open-source "MEWron" printer is bringing MEW to labs for a fraction of the cost of commercial machines
  • The two kinds of makers — builders vs. users — and where the community is heading
  • Paul's advice for clinicians and newcomers entering biofabrication

Plus, a remarkable offer for listeners at the end of this episode. 

đź”— Show notes

YouTube recording: Coming soon

Send us Fan Mail

Support the show

Subscribe to our premium version and support the show. 

Follow us:
Twitter 
Instagram
Linkedin
3DHEALS Website
Facebook
Facebook Group
Youtube channel

About Pitch3D 

]]> 3DHEALS Buzzsprout-19294545 Thu, 04 Jun 2026 13:00:00 -0400 3519 115 full false Episode #114| Interview With Brigitte de Vet-Veithen, CEO of Materialise Episode #114| Interview With Brigitte de Vet-Veithen, CEO of Materialise This is our second episode recorded at the Materialise conference.  Our guest for this episode is no other than the CEO of Materialise Brigitte de Vet-Veithen. It is a pleasure for me to be able to conduct this interview, because Materialise is such a legendary company that has spent 35 years building the software and services infrastructure behind patient-specific implants, surgical planning, and point-of-care manufacturing. We also got to know Brigitte as a person and the new leader of the company. Importantly, we covered the metrics that signal adoption, challenges to scale beyond the halo case, and her vision for the industry.  In my opinion, this is perhaps one of the most important conversations for the medical 3D printing industry in 2026.

Highlights of this episode:

• Brigitte's journey from MedTech leadership to being the CEO at Materialise
• Why reimbursement is the clearest signal of adoption for medical 3D printing
• Building health economics evidence for patient-specific devices when every case is unique
• Helping physicians shift mindset toward pre-operative planning and new workflows
• The move from “3D printing company” to solution partner for specific clinical needs
• Why robots and surgical guides coexist, especially in ambulatory surgery centers
• How AI compresses lead times and expands access for trauma patients
• Mass personalization roadmap across orthopedics, CMF, pediatrics, respiratory, and structural heart
• Global adoption differences and why imaging availability sets the pace
• Investment priorities across education, evidence generation, R&D, and M&A

Please listen to the disclaimer at the end of this podcast.


Show Notes: https://3dheals.com/episode-114-interview-with-brigitte-de-vet-veithen-ceo-of-materialise/

YouTube: https://youtu.be/9PgME2RAmog?si=t-0X_DkrBdRg4MHe





Send us Fan Mail

Support the show

Subscribe to our premium version and support the show. 

Follow us:
Twitter 
Instagram
Linkedin
3DHEALS Website
Facebook
Facebook Group
Youtube channel

About Pitch3D 

]]> This is our second episode recorded at the Materialise conference.  Our guest for this episode is no other than the CEO of Materialise Brigitte de Vet-Veithen. It is a pleasure for me to be able to conduct this interview, because Materialise is such a legendary company that has spent 35 years building the software and services infrastructure behind patient-specific implants, surgical planning, and point-of-care manufacturing. We also got to know Brigitte as a person and the new leader of the company. Importantly, we covered the metrics that signal adoption, challenges to scale beyond the halo case, and her vision for the industry.  In my opinion, this is perhaps one of the most important conversations for the medical 3D printing industry in 2026.

Highlights of this episode:

• Brigitte's journey from MedTech leadership to being the CEO at Materialise
• Why reimbursement is the clearest signal of adoption for medical 3D printing
• Building health economics evidence for patient-specific devices when every case is unique
• Helping physicians shift mindset toward pre-operative planning and new workflows
• The move from “3D printing company” to solution partner for specific clinical needs
• Why robots and surgical guides coexist, especially in ambulatory surgery centers
• How AI compresses lead times and expands access for trauma patients
• Mass personalization roadmap across orthopedics, CMF, pediatrics, respiratory, and structural heart
• Global adoption differences and why imaging availability sets the pace
• Investment priorities across education, evidence generation, R&D, and M&A

Please listen to the disclaimer at the end of this podcast.


Show Notes: https://3dheals.com/episode-114-interview-with-brigitte-de-vet-veithen-ceo-of-materialise/

YouTube: https://youtu.be/9PgME2RAmog?si=t-0X_DkrBdRg4MHe





Send us Fan Mail

Support the show

Subscribe to our premium version and support the show. 

Follow us:
Twitter 
Instagram
Linkedin
3DHEALS Website
Facebook
Facebook Group
Youtube channel

About Pitch3D 

]]> 3DHEALS Buzzsprout-19155198 Mon, 11 May 2026 00:00:00 -0400 2501 114 full false Episode#113| How 3D Printing Explains the Unexplainable in Congenital Heart Disease with Dr. Tristan Ramcharan Episode#113| How 3D Printing Explains the Unexplainable in Congenital Heart Disease with Dr. Tristan Ramcharan This is one of two episodes we have recorded during our trip to Leuven Belgium for the Materialise 2026 Conference, focusing on 3D planning and 3D printing in hospitals. We talked with Dr. Tristan Remcharan about how pediatric cardiology imaging can become something you can literally hold, using 3D segmentation and 3D printing to make congenital heart disease easier to plan, teach, and explain. We also dig into the 2D versus 3D generational divide and the real-world funding hurdles that decide whether point-of-care 3D becomes routine care. 

Show notes: https://3dheals.com/episode-113-how-3d-printing-explains-the-unexplainable-with-dr-tristan-ramcharan/

YouTube Video: https://youtu.be/eNUQWwJq5HM?si=3QhxXxvvUaEhO1MD

The 3D cardiac printing program at Birmingham Children's Hospital is funded by charitable donations. 

To support Tristan's works directly: Birmingham Children's Hospital Charity — https://www.bch.org.uk/appeal/donate

Donate to the 3D cardiac printing program

Send us Fan Mail

Support the show

Subscribe to our premium version and support the show. 

Follow us:
Twitter 
Instagram
Linkedin
3DHEALS Website
Facebook
Facebook Group
Youtube channel

About Pitch3D 

]]> This is one of two episodes we have recorded during our trip to Leuven Belgium for the Materialise 2026 Conference, focusing on 3D planning and 3D printing in hospitals. We talked with Dr. Tristan Remcharan about how pediatric cardiology imaging can become something you can literally hold, using 3D segmentation and 3D printing to make congenital heart disease easier to plan, teach, and explain. We also dig into the 2D versus 3D generational divide and the real-world funding hurdles that decide whether point-of-care 3D becomes routine care. 

Show notes: https://3dheals.com/episode-113-how-3d-printing-explains-the-unexplainable-with-dr-tristan-ramcharan/

YouTube Video: https://youtu.be/eNUQWwJq5HM?si=3QhxXxvvUaEhO1MD

The 3D cardiac printing program at Birmingham Children's Hospital is funded by charitable donations. 

To support Tristan's works directly: Birmingham Children's Hospital Charity — https://www.bch.org.uk/appeal/donate

Donate to the 3D cardiac printing program

Send us Fan Mail

Support the show

Subscribe to our premium version and support the show. 

Follow us:
Twitter 
Instagram
Linkedin
3DHEALS Website
Facebook
Facebook Group
Youtube channel

About Pitch3D 

]]> 3DHEALS Buzzsprout-19154249 Sun, 10 May 2026 19:00:00 -0400 962 full false Episode# 112 | Automating Compounding Pharmacies: Prof. Alvaro Goyanes, FabRx Episode# 112 | Automating Compounding Pharmacies: Prof. Alvaro Goyanes, FabRx You can learn a lot about the future of healthcare by watching how a single pill gets made. From a small office in London, we sit down with Prof Alvaro Goyanes, co-founder and CEO of FabRx, to unpack how 3D printed pharmaceuticals are turning personalized medicine from an idea into a working system. If you’ve ever wondered why patients still get forced into a handful of standard doses, this conversation shows what changes when medicine becomes software-driven and printable on demand. 

We talk about what FabRx is building, why they’ve stayed deeply research-led while pushing toward clinical application, and how partnerships with hospitals are translating 3D printing into real studies. We also get specific about the compounding pharmacy workflow: “pharma ink” syringes prepared ahead of time, doses selected in software, and tablets printed with controls that reduce manual steps and help cut inconsistency. It’s a practical look at personalized drug manufacturing for therapies that need flexible dosing across pediatrics, elderly care, hormones, and more. 

Quality is the backbone of everything here, so we dig into traceability, weighing each unit, pressure-sensing to catch extrusion problems early, camera systems that verify prints, and where AI inspection and near-infrared methods fit in. We zoom out to the policy layer, including the UK’s move toward distributed point-of-care manufacturing and how regulators in Europe and the US are beginning to shape guidance for 3D printing in pharmacies. Then we end on a wild but serious frontier: why NASA cares about printing medicines in space, where supply chains and gravity don’t cooperate. 

If you care about personalized medicine, 3D printing in healthcare, and the future of compounding pharmacies, hit subscribe, share this with a friend in pharma or medtech, and leave a review telling us what application you want to see next.

About Our Guest: 


Alvaro Goyanes is the co-founder and CEO of FABRX, the first company dedicated to developing 3D printing technology for the fabrication of personalized medicines and medical devices. He is also an Honorary Associate Professor at University College London- School of Pharmacy (UK) and an Associate Professor at the Faculty of Pharmacy, University of Santiago de Compostela (Spain).
A pioneer in the field, Alvaro was among the first researchers to explore the potential of 3D printing for manufacturing oral dosage forms and medical devices. Recognized as a world expert in 3D-printed medicines, he has been listed among the World's Most Highly Influential Researchers by Web of Science for six consecutive years since 2019.
Alvaro holds a PhD in Pharmaceutics from the University of Santiago de Compostela and previously worked as a Registered Pharmacist for three years, giving him firsthand insight into the needs of community pharmacy.

Show notes: Coming soon

YouTube: Coming soon

Send us Fan Mail

Support the show

Subscribe to our premium version and support the show. 

Follow us:
Twitter 
Instagram
Linkedin
3DHEALS Website
Facebook
Facebook Group
Youtube channel

About Pitch3D 

]]> You can learn a lot about the future of healthcare by watching how a single pill gets made. From a small office in London, we sit down with Prof Alvaro Goyanes, co-founder and CEO of FabRx, to unpack how 3D printed pharmaceuticals are turning personalized medicine from an idea into a working system. If you’ve ever wondered why patients still get forced into a handful of standard doses, this conversation shows what changes when medicine becomes software-driven and printable on demand. 

We talk about what FabRx is building, why they’ve stayed deeply research-led while pushing toward clinical application, and how partnerships with hospitals are translating 3D printing into real studies. We also get specific about the compounding pharmacy workflow: “pharma ink” syringes prepared ahead of time, doses selected in software, and tablets printed with controls that reduce manual steps and help cut inconsistency. It’s a practical look at personalized drug manufacturing for therapies that need flexible dosing across pediatrics, elderly care, hormones, and more. 

Quality is the backbone of everything here, so we dig into traceability, weighing each unit, pressure-sensing to catch extrusion problems early, camera systems that verify prints, and where AI inspection and near-infrared methods fit in. We zoom out to the policy layer, including the UK’s move toward distributed point-of-care manufacturing and how regulators in Europe and the US are beginning to shape guidance for 3D printing in pharmacies. Then we end on a wild but serious frontier: why NASA cares about printing medicines in space, where supply chains and gravity don’t cooperate. 

If you care about personalized medicine, 3D printing in healthcare, and the future of compounding pharmacies, hit subscribe, share this with a friend in pharma or medtech, and leave a review telling us what application you want to see next.

About Our Guest: 


Alvaro Goyanes is the co-founder and CEO of FABRX, the first company dedicated to developing 3D printing technology for the fabrication of personalized medicines and medical devices. He is also an Honorary Associate Professor at University College London- School of Pharmacy (UK) and an Associate Professor at the Faculty of Pharmacy, University of Santiago de Compostela (Spain).
A pioneer in the field, Alvaro was among the first researchers to explore the potential of 3D printing for manufacturing oral dosage forms and medical devices. Recognized as a world expert in 3D-printed medicines, he has been listed among the World's Most Highly Influential Researchers by Web of Science for six consecutive years since 2019.
Alvaro holds a PhD in Pharmaceutics from the University of Santiago de Compostela and previously worked as a Registered Pharmacist for three years, giving him firsthand insight into the needs of community pharmacy.

Show notes: Coming soon

YouTube: Coming soon

Send us Fan Mail

Support the show

Subscribe to our premium version and support the show. 

Follow us:
Twitter 
Instagram
Linkedin
3DHEALS Website
Facebook
Facebook Group
Youtube channel

About Pitch3D 

]]> 3DHEALS Buzzsprout-19066031 Thu, 23 Apr 2026 11:00:00 -0400 933 112 full false Episode #110 | Neurotech Investing With Varun Turlapati, Chaanakya Capital Episode #110 | Neurotech Investing With Varun Turlapati, Chaanakya Capital Neurotech is the category most investors whisper about and then walk away from: too technical, too regulated, too slow. We wanted to talk to someone who leans in anyway, so I sat down with Varun Turlapati, founder of Chanakya Capital, to hear how he’s building an early-stage fund dedicated to neurotech devices and why he thinks the “long horizon” objection often misses what’s actually happening on the ground.

We unpack Varun’s path from software engineering into venture capital, including the mindset shift from analysis paralysis to fast iteration with smart guardrails. From there, we widen the frame on what neurotech means. Yes, brain-computer interfaces matter, but we also get into neuromodulation, bioelectronics, and the nervous system as the body’s command network, linking the brain, gut, and heart, and addressing disease. That lens turns “niche” into “everyone with a brain,” and it changes how you think about markets, clinical impact, and investable product strategy.

Varun also shares the practical mechanics of deep tech investing: how he triages an 80+ company pipeline, separates “interesting” from “investable,” and brings in PhD scientists, physicians, and specialist advisors to evaluate clinical workflows and real differentiation. We dive into real examples across neuroprosthetics, Alzheimer’s, ADHD, and autism wearables, and a smart shunt for hydrocephalus, plus how regulatory signals like Breakthrough Device Designation can reshape the risk profile.

If you care about neurotech startups, medical devices, FDA pathways, or where venture capital goes after AI becomes commoditized, this conversation will sharpen your evaluation of both science and execution. Subscribe to Lattice, share this with a founder or investor who’s curious about neurotech, and leave a review with the biggest question you still have about building in this space.


Show notes: https://3dheals.com/episode-110-neurotech-investing-with-varun-turlapati-chaanakya-capital/

YouTube recording: coming soon

Send us Fan Mail

Support the show

Subscribe to our premium version and support the show. 

Follow us:
Twitter 
Instagram
Linkedin
3DHEALS Website
Facebook
Facebook Group
Youtube channel

About Pitch3D 

]]> Neurotech is the category most investors whisper about and then walk away from: too technical, too regulated, too slow. We wanted to talk to someone who leans in anyway, so I sat down with Varun Turlapati, founder of Chanakya Capital, to hear how he’s building an early-stage fund dedicated to neurotech devices and why he thinks the “long horizon” objection often misses what’s actually happening on the ground.

We unpack Varun’s path from software engineering into venture capital, including the mindset shift from analysis paralysis to fast iteration with smart guardrails. From there, we widen the frame on what neurotech means. Yes, brain-computer interfaces matter, but we also get into neuromodulation, bioelectronics, and the nervous system as the body’s command network, linking the brain, gut, and heart, and addressing disease. That lens turns “niche” into “everyone with a brain,” and it changes how you think about markets, clinical impact, and investable product strategy.

Varun also shares the practical mechanics of deep tech investing: how he triages an 80+ company pipeline, separates “interesting” from “investable,” and brings in PhD scientists, physicians, and specialist advisors to evaluate clinical workflows and real differentiation. We dive into real examples across neuroprosthetics, Alzheimer’s, ADHD, and autism wearables, and a smart shunt for hydrocephalus, plus how regulatory signals like Breakthrough Device Designation can reshape the risk profile.

If you care about neurotech startups, medical devices, FDA pathways, or where venture capital goes after AI becomes commoditized, this conversation will sharpen your evaluation of both science and execution. Subscribe to Lattice, share this with a founder or investor who’s curious about neurotech, and leave a review with the biggest question you still have about building in this space.


Show notes: https://3dheals.com/episode-110-neurotech-investing-with-varun-turlapati-chaanakya-capital/

YouTube recording: coming soon

Send us Fan Mail

Support the show

Subscribe to our premium version and support the show. 

Follow us:
Twitter 
Instagram
Linkedin
3DHEALS Website
Facebook
Facebook Group
Youtube channel

About Pitch3D 

]]> 3DHEALS Buzzsprout-18992068 Thu, 09 Apr 2026 20:00:00 -0400 3723 110 full false Episode #109| March Newsletter: From Bioprinted Organs To FDA Cleared Implants In Healthcare 3D Printing Episode #109| March Newsletter: From Bioprinted Organs To FDA Cleared Implants In Healthcare 3D Printing We track the biggest healthcare 3D printing stories from March 2026, from bioprinted organs and sustainable bioinks to FDA-cleared implants and hospital point-of-care wins. We also look at how 3D printed cancer tools, training models, microrobots, and AI quality control are moving from research into real clinical and manufacturing workflows. 
• bioprinted uterus model for preterm labor drug testing and future personalization 
• ENLIGHT pancreas project using volumetric bioprinting and long viability gels for diabetes research 
• vascularized adipose tissue implants for soft tissue repair and breast reconstruction 
• Singapore biofabrication roadmap focused on sustainable biomaterials and circular supply chains 
• FDA 510(k) cleared titanium spinal implant plus trends in lumbar cage materials and coatings 
• EU MDR certified denture manufacturing and implications for scaled dental 3D printing 
• 3D printed breast cancer locator improving surgical margins with patient-specific guides 
• 3D printed metastasis research platform showing fibroblast protection in blood flow stress 
• brain phantoms and beating heart simulators for realistic surgical training 
• bioprinted cardiac spheroids for studying SARS-CoV-2 heart infection and drug testing 
• microrobots, AI defect prediction, volumetric production methods, and micro-scale printers 
• hospital-made rehab devices cutting costs and a reality check on AI-driven implants 
Please subscribe for more future updates and let us know if anything is missing or incorrect. 


Complete show notes, including links to all articles mentioned in this podcast, are here. 


Send us Fan Mail

Support the show

Subscribe to our premium version and support the show. 

Follow us:
Twitter 
Instagram
Linkedin
3DHEALS Website
Facebook
Facebook Group
Youtube channel

About Pitch3D 

]]> We track the biggest healthcare 3D printing stories from March 2026, from bioprinted organs and sustainable bioinks to FDA-cleared implants and hospital point-of-care wins. We also look at how 3D printed cancer tools, training models, microrobots, and AI quality control are moving from research into real clinical and manufacturing workflows. 
• bioprinted uterus model for preterm labor drug testing and future personalization 
• ENLIGHT pancreas project using volumetric bioprinting and long viability gels for diabetes research 
• vascularized adipose tissue implants for soft tissue repair and breast reconstruction 
• Singapore biofabrication roadmap focused on sustainable biomaterials and circular supply chains 
• FDA 510(k) cleared titanium spinal implant plus trends in lumbar cage materials and coatings 
• EU MDR certified denture manufacturing and implications for scaled dental 3D printing 
• 3D printed breast cancer locator improving surgical margins with patient-specific guides 
• 3D printed metastasis research platform showing fibroblast protection in blood flow stress 
• brain phantoms and beating heart simulators for realistic surgical training 
• bioprinted cardiac spheroids for studying SARS-CoV-2 heart infection and drug testing 
• microrobots, AI defect prediction, volumetric production methods, and micro-scale printers 
• hospital-made rehab devices cutting costs and a reality check on AI-driven implants 
Please subscribe for more future updates and let us know if anything is missing or incorrect. 


Complete show notes, including links to all articles mentioned in this podcast, are here. 


Send us Fan Mail

Support the show

Subscribe to our premium version and support the show. 

Follow us:
Twitter 
Instagram
Linkedin
3DHEALS Website
Facebook
Facebook Group
Youtube channel

About Pitch3D 

]]> 3DHEALS Buzzsprout-18923727 Sun, 29 Mar 2026 00:00:00 -0400 661 109 full false Episode #108 | Teleporting Medicine with 3D Printing - Dr. Stephen Ryan, PolyUnity Episode #108 | Teleporting Medicine with 3D Printing - Dr. Stephen Ryan, PolyUnity What happens when a hospital needs a simple part but the supply chain takes weeks or months to deliver it? Dr. Stephan Ryan, physician and co-founder of PolyUnity, set out to solve that problem by helping hospitals produce parts themselves through safe, compliant 3D printing. In this episode, Stephen Ryan shares how early clinical experiences and an academic 3D printing lab evolved into a platform designed to help hospitals manufacture equipment on demand. The COVID pandemic accelerated that vision, exposing major supply chain gaps and pushing the team to rapidly scale production. Stephen Ryan explains how those lessons shaped PolyUnity’s approach to building practical additive manufacturing systems within the realities of healthcare procurement, regulation, and hospital workflows.

Bullet points:

• Defining PolyUnity’s mission to democratize hospital 3D printing with compliant workflows
• The rural hospital supply chain problem that sparked the original research project
• How COVID accelerated real-world production and forced end-to-end process design
• Why post-pandemic red tape returned and how it shaped the software moat
• Bootstrapping a medtech startup in Canada with long procurement cycles
• Building a small team and staying capital efficient through iterative deployment
• Good and "bad" ideas for hospital 3D printing applications
• High-ROI case applications that avoid big spend
• Distributed manufacturing hubs and the practical path toward on-site production
• The wisdom of choosing simple over complexity.
• Post-processing bottlenecks and what are potential solutions.
• Personal transformation from clinician to entrepreneur.
 
Show notes: https://3dheals.com/teleporting-medicine-with-3d-printing-dr-stephen-ryan-of-polyunity-interview/

Full video interview: https://youtu.be/cO7mTr5GLJ8?si=icmU03OI1cPDZJL9

About our guest: 

Dr. Stephen Ryan is a physician, entrepreneur, and the co-founder and Chief Medical Officer of PolyUnity, a Canadian health tech company focused on lowering the barrier for hospitals to adopt 3D printing through its i3D platform and solutions. His work centers on building software, quality systems, and distributed print capacity so that hospitals can reliably order and receive end use 3D printed parts, from simple fixtures to clinically relevant devices, within existing procurement and regulatory frameworks.


Send us Fan Mail

Support the show

Subscribe to our premium version and support the show. 

Follow us:
Twitter 
Instagram
Linkedin
3DHEALS Website
Facebook
Facebook Group
Youtube channel

About Pitch3D 

]]> What happens when a hospital needs a simple part but the supply chain takes weeks or months to deliver it? Dr. Stephan Ryan, physician and co-founder of PolyUnity, set out to solve that problem by helping hospitals produce parts themselves through safe, compliant 3D printing. In this episode, Stephen Ryan shares how early clinical experiences and an academic 3D printing lab evolved into a platform designed to help hospitals manufacture equipment on demand. The COVID pandemic accelerated that vision, exposing major supply chain gaps and pushing the team to rapidly scale production. Stephen Ryan explains how those lessons shaped PolyUnity’s approach to building practical additive manufacturing systems within the realities of healthcare procurement, regulation, and hospital workflows.

Bullet points:

• Defining PolyUnity’s mission to democratize hospital 3D printing with compliant workflows
• The rural hospital supply chain problem that sparked the original research project
• How COVID accelerated real-world production and forced end-to-end process design
• Why post-pandemic red tape returned and how it shaped the software moat
• Bootstrapping a medtech startup in Canada with long procurement cycles
• Building a small team and staying capital efficient through iterative deployment
• Good and "bad" ideas for hospital 3D printing applications
• High-ROI case applications that avoid big spend
• Distributed manufacturing hubs and the practical path toward on-site production
• The wisdom of choosing simple over complexity.
• Post-processing bottlenecks and what are potential solutions.
• Personal transformation from clinician to entrepreneur.
 
Show notes: https://3dheals.com/teleporting-medicine-with-3d-printing-dr-stephen-ryan-of-polyunity-interview/

Full video interview: https://youtu.be/cO7mTr5GLJ8?si=icmU03OI1cPDZJL9

About our guest: 

Dr. Stephen Ryan is a physician, entrepreneur, and the co-founder and Chief Medical Officer of PolyUnity, a Canadian health tech company focused on lowering the barrier for hospitals to adopt 3D printing through its i3D platform and solutions. His work centers on building software, quality systems, and distributed print capacity so that hospitals can reliably order and receive end use 3D printed parts, from simple fixtures to clinically relevant devices, within existing procurement and regulatory frameworks.


Send us Fan Mail

Support the show

Subscribe to our premium version and support the show. 

Follow us:
Twitter 
Instagram
Linkedin
3DHEALS Website
Facebook
Facebook Group
Youtube channel

About Pitch3D 

]]> 3DHEALS Buzzsprout-18839669 Sat, 14 Mar 2026 11:00:00 -0400 3358 108 full false Episode#107 | The Lattice Feb 2026 - Latest News in Healthcare 3D Printing Episode#107 | The Lattice Feb 2026 - Latest News in Healthcare 3D Printing We map the biggest shifts in healthcare 3D printing this month, from emissions safety to custom eyewear, implant surfaces, microfluidics, and space-based biomanufacturing. We weigh promise against risk and share where standards and design can close the gap.

• emissions from desktop and industrial printers and why they matter 
• safeguards for vulnerable groups and safer materials and testing 
• face-scan eyewear, on-demand manufacturing, and fashion collaborations 
• implant surface roughness, porosity, coatings, and clinical outcomes 
• ceramic, titanium, and PEEK devices for spine, ankle, and CMF 
• microfluidics for diagnostics and microneedle vaccines and immunotherapy 
• digital microfluidics and 3D cell culture for faster R&D 
• microgravity biomanufacturing and what space enables for medicine


See blog post related to this podcast: https://3dheals.com/the-lattice-feb-2026-advanced-devices-custom-eyewear-and-hidden-health-risks-of-3d-printing/



Send us Fan Mail

Support the show

Subscribe to our premium version and support the show. 

Follow us:
Twitter 
Instagram
Linkedin
3DHEALS Website
Facebook
Facebook Group
Youtube channel

About Pitch3D 

]]> We map the biggest shifts in healthcare 3D printing this month, from emissions safety to custom eyewear, implant surfaces, microfluidics, and space-based biomanufacturing. We weigh promise against risk and share where standards and design can close the gap.

• emissions from desktop and industrial printers and why they matter 
• safeguards for vulnerable groups and safer materials and testing 
• face-scan eyewear, on-demand manufacturing, and fashion collaborations 
• implant surface roughness, porosity, coatings, and clinical outcomes 
• ceramic, titanium, and PEEK devices for spine, ankle, and CMF 
• microfluidics for diagnostics and microneedle vaccines and immunotherapy 
• digital microfluidics and 3D cell culture for faster R&D 
• microgravity biomanufacturing and what space enables for medicine


See blog post related to this podcast: https://3dheals.com/the-lattice-feb-2026-advanced-devices-custom-eyewear-and-hidden-health-risks-of-3d-printing/



Send us Fan Mail

Support the show

Subscribe to our premium version and support the show. 

Follow us:
Twitter 
Instagram
Linkedin
3DHEALS Website
Facebook
Facebook Group
Youtube channel

About Pitch3D 

]]> 3DHEALS Buzzsprout-18729377 Mon, 23 Feb 2026 00:00:00 -0500 410 107 full false Episode #106| Bionic Hands For Humans and Robots: The Psyonic Story Episode #106| Bionic Hands For Humans and Robots: The Psyonic Story We share how a decade of soft robotics, open APIs, and relentless iteration turned a 3D-printed prototype into a durable, touch-sensing bionic hand used by amputees and robots. Stories of failure, funding, and firsts reveal how speed, sensation, and design choices translate to real lives and real factories.

• early 3D printing wins and durability limits
• shift to soft robotics, silicone overmolding, carbon fiber reinforcement
• founding spark, Ecuador trial, and move from academia to company
• SBIR lifeline, failed crowdfunding, then coverage and clinical validation
• speed, grip force, and touch sensors compared with the market
• open API for control and data streaming in minutes
• robotics crossover in automotive and research labs
• access initiatives via the Ability Fund and global impact
• manufacturing scale plans and ethical boundaries
• practical founder habits, grit, and advice to start now

Please listen to the disclaimer at the end of this podcast

Show notes: https://3dheals.com/aadeel-akhtar-bionic-hands-for-humans-and-robots-the-psyonic-story/

YouTube: https://youtu.be/mDVMRhjXr0w?si=qoZrScjaC6nbiPMJ

About our guest:


Dr. Aadeel Akhtar, CEO of PSYONIC, founded the company to create advanced, accessible bionic limbs after meeting a young girl in Pakistan who was missing a limb. PSYONIC's bionic Ability Hand is the fastest on the market, impact-resistant, and the first to provide a sense of touch. It is also covered by Medicare and is being used by humans and robotics companies globally, including NASA, Meta, Mercedes, and Google. Dr. Akhtar earned a Ph.D. in Neuroscience and an M.S. in Electrical & Computer Engineering from the University of Illinois, along with a B.S. in Biology and an M.S. in Computer Science from Loyola University Chicago. He’s been recognized by MIT Technology Review and Newsweek and secured a 3-shark deal on Shark Tank. 




Send us Fan Mail

Support the show

Subscribe to our premium version and support the show. 

Follow us:
Twitter 
Instagram
Linkedin
3DHEALS Website
Facebook
Facebook Group
Youtube channel

About Pitch3D 

]]> We share how a decade of soft robotics, open APIs, and relentless iteration turned a 3D-printed prototype into a durable, touch-sensing bionic hand used by amputees and robots. Stories of failure, funding, and firsts reveal how speed, sensation, and design choices translate to real lives and real factories.

• early 3D printing wins and durability limits
• shift to soft robotics, silicone overmolding, carbon fiber reinforcement
• founding spark, Ecuador trial, and move from academia to company
• SBIR lifeline, failed crowdfunding, then coverage and clinical validation
• speed, grip force, and touch sensors compared with the market
• open API for control and data streaming in minutes
• robotics crossover in automotive and research labs
• access initiatives via the Ability Fund and global impact
• manufacturing scale plans and ethical boundaries
• practical founder habits, grit, and advice to start now

Please listen to the disclaimer at the end of this podcast

Show notes: https://3dheals.com/aadeel-akhtar-bionic-hands-for-humans-and-robots-the-psyonic-story/

YouTube: https://youtu.be/mDVMRhjXr0w?si=qoZrScjaC6nbiPMJ

About our guest:


Dr. Aadeel Akhtar, CEO of PSYONIC, founded the company to create advanced, accessible bionic limbs after meeting a young girl in Pakistan who was missing a limb. PSYONIC's bionic Ability Hand is the fastest on the market, impact-resistant, and the first to provide a sense of touch. It is also covered by Medicare and is being used by humans and robotics companies globally, including NASA, Meta, Mercedes, and Google. Dr. Akhtar earned a Ph.D. in Neuroscience and an M.S. in Electrical & Computer Engineering from the University of Illinois, along with a B.S. in Biology and an M.S. in Computer Science from Loyola University Chicago. He’s been recognized by MIT Technology Review and Newsweek and secured a 3-shark deal on Shark Tank. 




Send us Fan Mail

Support the show

Subscribe to our premium version and support the show. 

Follow us:
Twitter 
Instagram
Linkedin
3DHEALS Website
Facebook
Facebook Group
Youtube channel

About Pitch3D 

]]> 3DHEALS Buzzsprout-18724365 Sat, 21 Feb 2026 21:00:00 -0500 3231 106 full false Episode #105 | Jan 2026 News: ARPA-H Organ "Moonshots", Point-of-Care Manufacturing, and More Episode #105 | Jan 2026 News: ARPA-H Organ "Moonshots", Point-of-Care Manufacturing, and More We track a month of fast-moving news in healthcare 3D printing, from organ-scale bioprinting programs and ARPA-H’s funding model to point-of-care tools already entering clinics. The throughline is clear: vascularization, immune compatibility, and scale are converging with real-world deployment.

• UT Southwestern’s organoid-plus-bioprinting strategy for durable liver tissue
• Carnegie Mellon’s consortium on vascularization, immune control, and scale
• ARPA-H’s moonshot funding model is accelerating medical innovation
• Aspect Biosystems and Novo Nordisk’s bet on curing diabetes
• Cost shift from chronic management to curative therapies
• Near-term point-of-care printing: Curify Labs and AZORG integrations
• Key milestone to watch: functional vascular networks
• Outlook as research, industry, and funding align

Remember, this podcast is for educational and informational purposes only
The views expressed do not constitute engineering, medical, or financial advice. The technologies and procedures discussed may not be commercially available or suitable for every case. Always consult with a qualified professional

Shownotes: https://3dheals.com/lattice-news-arpa-h-organ-moonshots-point-of-care-manufacturing-and-more/




Send us Fan Mail

Support the show

Subscribe to our premium version and support the show. 

Follow us:
Twitter 
Instagram
Linkedin
3DHEALS Website
Facebook
Facebook Group
Youtube channel

About Pitch3D 

]]> We track a month of fast-moving news in healthcare 3D printing, from organ-scale bioprinting programs and ARPA-H’s funding model to point-of-care tools already entering clinics. The throughline is clear: vascularization, immune compatibility, and scale are converging with real-world deployment.

• UT Southwestern’s organoid-plus-bioprinting strategy for durable liver tissue
• Carnegie Mellon’s consortium on vascularization, immune control, and scale
• ARPA-H’s moonshot funding model is accelerating medical innovation
• Aspect Biosystems and Novo Nordisk’s bet on curing diabetes
• Cost shift from chronic management to curative therapies
• Near-term point-of-care printing: Curify Labs and AZORG integrations
• Key milestone to watch: functional vascular networks
• Outlook as research, industry, and funding align

Remember, this podcast is for educational and informational purposes only
The views expressed do not constitute engineering, medical, or financial advice. The technologies and procedures discussed may not be commercially available or suitable for every case. Always consult with a qualified professional

Shownotes: https://3dheals.com/lattice-news-arpa-h-organ-moonshots-point-of-care-manufacturing-and-more/




Send us Fan Mail

Support the show

Subscribe to our premium version and support the show. 

Follow us:
Twitter 
Instagram
Linkedin
3DHEALS Website
Facebook
Facebook Group
Youtube channel

About Pitch3D 

]]> 3DHEALS Buzzsprout-18568458 Sun, 25 Jan 2026 20:00:00 -0500 313 105 full false Episode #102 | Can Bioprinting Reshape The Future of Immunology? Episode #102 | Can Bioprinting Reshape The Future of Immunology? We explore how to move IVIG from donor scarcity to on‑demand manufacturing with tissue‑engineered bioreactors, and why that shift could lower costs, expand access, and improve consistency. We dig into polyclonal advantages, regulatory guardrails, scaling plans, and what success would mean for complex biologics beyond antibodies.

• Defining a bioreactor that recreates human tissue niches
• Why polyclonal IVIG remains essential across 100+ conditions
• Limits of donor‑dependent plasma supply and regional variability
• Complex therapeutics as a new manufacturing category
• Cost targets of 10–100x reduction and CapEx shrink
• Coffee‑cup reactors and near‑term validation milestones
• Quality metrics including pathogen panels and glycosylation
• Donor variability, blending strategies, and future immortalization
• Clinical impact of moving from rationing to earlier use
• Funding update and industry partnerships

Please listen to the disclaimer at the end of this podcast.

Show notes: https://3dheals.com/episode-102-can-bioprinting-bioreactor-reshape-the-future-of-immunology/


About our guests:

Dr. Melanie Matheu is an immunologist, inventor, and biotechnologist recognized for pioneering work in high-resolution tissue engineering and human immunology. She received her PhD in Physiology and Biophysics with a focus on Immunology from UC Irvine and completed postdoctoral training at VIB (Ghent University, Belgium) and UC San Francisco, where she specialized in 2-photon imaging and cellular immune responses. As founder of Prellis Biologics, Dr. Matheu brought forward laser-based tissue bioprinting to solve complex challenges in organ transplantation and therapeutic antibody discovery. She later co-founded Lyric Bio, where she serves as Chief Scientific Officer, advancing scalable biomanufacturing platforms and rapid human immune system modeling. Dr. Matheu has authored numerous peer-reviewed publications, holds multiple patents, and is a passionate advocate for innovation at the intersection of immunology and bioengineering.


Kevin Shannon (Kayj) holds a degree in Molecular Biology from Princeton University and a MBA from Stanford Graduate School of Business. Kayj has held positions spanning the biotech ecosystem including start-ups, big pharma, venture capital, and consulting. As part of Corporate Strategy at Amgen, he worked with Amgen’s C-Suite to shape long-term strategy, built partnerships in novel therapeutic modalities, and led investments in emerging categories including cell & gene therapy, antibody engineering, single cell analysis, and quantum computing. Kayj has also consulted for multiple VC funds where he developed investment theses and performed diligence in emerging technologies. Most recently, led business development for Zafrens, raising >$20M and securing two pharma company partnerships.

Kayj was first introduced to Melanie and the Prellis bioprinting technology when she brought him on as a consultant to evaluate initial applications for the company’s technology. Because of their strong working relationship and the remarkable nature of the technology, Kayj is excited to reunite with Melanie and join Lyric as CEO.



Send us Fan Mail

Support the show

Subscribe to our premium version and support the show. 

Follow us:
Twitter 
Instagram
Linkedin
3DHEALS Website
Facebook
Facebook Group
Youtube channel

About Pitch3D 

]]> We explore how to move IVIG from donor scarcity to on‑demand manufacturing with tissue‑engineered bioreactors, and why that shift could lower costs, expand access, and improve consistency. We dig into polyclonal advantages, regulatory guardrails, scaling plans, and what success would mean for complex biologics beyond antibodies.

• Defining a bioreactor that recreates human tissue niches
• Why polyclonal IVIG remains essential across 100+ conditions
• Limits of donor‑dependent plasma supply and regional variability
• Complex therapeutics as a new manufacturing category
• Cost targets of 10–100x reduction and CapEx shrink
• Coffee‑cup reactors and near‑term validation milestones
• Quality metrics including pathogen panels and glycosylation
• Donor variability, blending strategies, and future immortalization
• Clinical impact of moving from rationing to earlier use
• Funding update and industry partnerships

Please listen to the disclaimer at the end of this podcast.

Show notes: https://3dheals.com/episode-102-can-bioprinting-bioreactor-reshape-the-future-of-immunology/


About our guests:

Dr. Melanie Matheu is an immunologist, inventor, and biotechnologist recognized for pioneering work in high-resolution tissue engineering and human immunology. She received her PhD in Physiology and Biophysics with a focus on Immunology from UC Irvine and completed postdoctoral training at VIB (Ghent University, Belgium) and UC San Francisco, where she specialized in 2-photon imaging and cellular immune responses. As founder of Prellis Biologics, Dr. Matheu brought forward laser-based tissue bioprinting to solve complex challenges in organ transplantation and therapeutic antibody discovery. She later co-founded Lyric Bio, where she serves as Chief Scientific Officer, advancing scalable biomanufacturing platforms and rapid human immune system modeling. Dr. Matheu has authored numerous peer-reviewed publications, holds multiple patents, and is a passionate advocate for innovation at the intersection of immunology and bioengineering.


Kevin Shannon (Kayj) holds a degree in Molecular Biology from Princeton University and a MBA from Stanford Graduate School of Business. Kayj has held positions spanning the biotech ecosystem including start-ups, big pharma, venture capital, and consulting. As part of Corporate Strategy at Amgen, he worked with Amgen’s C-Suite to shape long-term strategy, built partnerships in novel therapeutic modalities, and led investments in emerging categories including cell & gene therapy, antibody engineering, single cell analysis, and quantum computing. Kayj has also consulted for multiple VC funds where he developed investment theses and performed diligence in emerging technologies. Most recently, led business development for Zafrens, raising >$20M and securing two pharma company partnerships.

Kayj was first introduced to Melanie and the Prellis bioprinting technology when she brought him on as a consultant to evaluate initial applications for the company’s technology. Because of their strong working relationship and the remarkable nature of the technology, Kayj is excited to reunite with Melanie and join Lyric as CEO.



Send us Fan Mail

Support the show

Subscribe to our premium version and support the show. 

Follow us:
Twitter 
Instagram
Linkedin
3DHEALS Website
Facebook
Facebook Group
Youtube channel

About Pitch3D 

]]> 3DHEALS Buzzsprout-18381856 Thu, 18 Dec 2025 19:00:00 -0500 2494 LyricBio, Bioreactor, Biotechnology, IVIG, Human Tissue, Bioprinting, Therapeutics, Innovation, Healthcare, Biotech Industry, Melanie Matheu, Kayj Shannon, Podcast Episode, Medical Advancements, Future of Medicine 102 full false Episode #101 | Therapeutic Hardware: Can Implants Also Heal? With Alyssa Huffman Allumin8 Episode #101 | Therapeutic Hardware: Can Implants Also Heal? With Alyssa Huffman Allumin8 In this episode, Alyssa Huffman, CEO and co-founder of Allumin8, shares the six-year journey behind a first-of-its-kind 5.5 mm porous, 3D-printed pedicle screw. We discussed how Allumin8 earned FDA clearance and why design details matter for fatigue, fixation, and fewer revisions. We also map a path toward therapeutic hardware that integrates orthobiologics without slowing surgeons down.

Critical questions addressed:

Why does 5.5 mm matter so much?

How does Gaussian topography support bone ingrowth?
What are some of the lessons from fatigue testing and post-processing?
What are the additive vs milled manufacturing trade-offs?
What was Allumin8's FDA journey and strategy?
When and how do orthobiologics add value?
How did Alyssa build a purpose-aligned team and investor base?
What are some practical founder advice on equity and boards?
What is on Alyssa's wishlist for the future of orthopedic implants? 


Please listen to the disclaimer at the end of this podcast.

Stay tuned for our show notes for relevant links, video highlights, glossary of terms, and more resources to enjoy this episode. 



Send us Fan Mail

Support the show

Subscribe to our premium version and support the show. 

Follow us:
Twitter 
Instagram
Linkedin
3DHEALS Website
Facebook
Facebook Group
Youtube channel

About Pitch3D 

]]> In this episode, Alyssa Huffman, CEO and co-founder of Allumin8, shares the six-year journey behind a first-of-its-kind 5.5 mm porous, 3D-printed pedicle screw. We discussed how Allumin8 earned FDA clearance and why design details matter for fatigue, fixation, and fewer revisions. We also map a path toward therapeutic hardware that integrates orthobiologics without slowing surgeons down.

Critical questions addressed:

Why does 5.5 mm matter so much?

How does Gaussian topography support bone ingrowth?
What are some of the lessons from fatigue testing and post-processing?
What are the additive vs milled manufacturing trade-offs?
What was Allumin8's FDA journey and strategy?
When and how do orthobiologics add value?
How did Alyssa build a purpose-aligned team and investor base?
What are some practical founder advice on equity and boards?
What is on Alyssa's wishlist for the future of orthopedic implants? 


Please listen to the disclaimer at the end of this podcast.

Stay tuned for our show notes for relevant links, video highlights, glossary of terms, and more resources to enjoy this episode. 



Send us Fan Mail

Support the show

Subscribe to our premium version and support the show. 

Follow us:
Twitter 
Instagram
Linkedin
3DHEALS Website
Facebook
Facebook Group
Youtube channel

About Pitch3D 

]]> 3DHEALS Buzzsprout-18264272 Thu, 27 Nov 2025 17:00:00 -0500 4084 3D printed implant, additive manufacturing, Spine Surgery, FDA Approval, Orthobiologics, Entrepreneurship, Allumin8 101 full false Episode #98 | Meeting the Bioprinting Vascular Challenge: VoxCell CEO Dr. Karolina Valente Episode #98 | Meeting the Bioprinting Vascular Challenge: VoxCell CEO Dr. Karolina Valente In this episode, Dr. Karolina Valente, Founder and CEO of VoxCell BioInnovation, discusses her journey in biotechnology, focusing on 3D bioprinting and its impact on cancer research and drug discovery. She shares insights into her leadership at VoxCell, the company's growth, and the accolades it has received. Dr. Valente also talks about the importance of partnerships, the future of biotechnology, and her personal experiences that drive her passion for innovation.

Questions answered:


  • How did Karolina first get involved with entrepreneurship and founding VoxCell BioInnovation?
  • What was it like to start a career across multiple continents? (From Brazil to Canada)
  • How to switch the hat from a scientist to a company founder?
  • What were some of the early milestones in the VoxCell journey that were impactful to the company today?
  • What is the core technology of the 3D bioprinting platform at VoxCell?
  • How does VoxCell’s technology address the Vascular Challenge in cancer research?
  • What kind of data do you provide in preclinical studies, and how does it compare to animal models?
  • How does Karolina navigate and build company culture at VoxCell?
  • What advice does Karolina have for young entrepreneurs and students in school?


See full show notes, links, and resources.

Send us Fan Mail

Support the show

Subscribe to our premium version and support the show. 

Follow us:
Twitter 
Instagram
Linkedin
3DHEALS Website
Facebook
Facebook Group
Youtube channel

About Pitch3D 

]]> In this episode, Dr. Karolina Valente, Founder and CEO of VoxCell BioInnovation, discusses her journey in biotechnology, focusing on 3D bioprinting and its impact on cancer research and drug discovery. She shares insights into her leadership at VoxCell, the company's growth, and the accolades it has received. Dr. Valente also talks about the importance of partnerships, the future of biotechnology, and her personal experiences that drive her passion for innovation.

Questions answered:


  • How did Karolina first get involved with entrepreneurship and founding VoxCell BioInnovation?
  • What was it like to start a career across multiple continents? (From Brazil to Canada)
  • How to switch the hat from a scientist to a company founder?
  • What were some of the early milestones in the VoxCell journey that were impactful to the company today?
  • What is the core technology of the 3D bioprinting platform at VoxCell?
  • How does VoxCell’s technology address the Vascular Challenge in cancer research?
  • What kind of data do you provide in preclinical studies, and how does it compare to animal models?
  • How does Karolina navigate and build company culture at VoxCell?
  • What advice does Karolina have for young entrepreneurs and students in school?


See full show notes, links, and resources.

Send us Fan Mail

Support the show

Subscribe to our premium version and support the show. 

Follow us:
Twitter 
Instagram
Linkedin
3DHEALS Website
Facebook
Facebook Group
Youtube channel

About Pitch3D 

]]> 3DHEALS Buzzsprout-18133272 Tue, 04 Nov 2025 15:00:00 -0500 3876 Karolina Valente, VoxCell, 3D bioprinting, cancer research, drug discovery, biotechnology, leadership, partnerships, innovation 98 full false Episode # 97 | Is ChatGPT Making Us Dumb? Episode # 97 | Is ChatGPT Making Us Dumb? Summary

In this conversation, Jenny Chen explores the complex implications of ChatGPT on intelligence and education. She emphasizes the need for careful consideration of the technology's impact, particularly in academic settings, and discusses the broader context of a technological revolution that may have both positive and negative consequences.


Takeaways

  • Is ChatGPT making us dumb?
  • This is a much more complicated question.
  • ChatGPT is problematic, especially for students.
  • We should consider this carefully and thoughtfully.
  • We're at a juncture of technological revolution.
  • Revolutions typically will have some casualties.
  • How can we use this new tool effectively?
  • Maximize our productivity without diminishing humanity.
  • Not causing something unthinkable, like being ruled by AI.
  • The good and evil of this very potent tool.


Show Notes: 

https://3dheals.com/is-chatgtp-or-ai-making-us-stupid-two-cents/




 

Send us Fan Mail

Support the show

Subscribe to our premium version and support the show. 

Follow us:
Twitter 
Instagram
Linkedin
3DHEALS Website
Facebook
Facebook Group
Youtube channel

About Pitch3D 

]]> Summary

In this conversation, Jenny Chen explores the complex implications of ChatGPT on intelligence and education. She emphasizes the need for careful consideration of the technology's impact, particularly in academic settings, and discusses the broader context of a technological revolution that may have both positive and negative consequences.


Takeaways

  • Is ChatGPT making us dumb?
  • This is a much more complicated question.
  • ChatGPT is problematic, especially for students.
  • We should consider this carefully and thoughtfully.
  • We're at a juncture of technological revolution.
  • Revolutions typically will have some casualties.
  • How can we use this new tool effectively?
  • Maximize our productivity without diminishing humanity.
  • Not causing something unthinkable, like being ruled by AI.
  • The good and evil of this very potent tool.


Show Notes: 

https://3dheals.com/is-chatgtp-or-ai-making-us-stupid-two-cents/




 

Send us Fan Mail

Support the show

Subscribe to our premium version and support the show. 

Follow us:
Twitter 
Instagram
Linkedin
3DHEALS Website
Facebook
Facebook Group
Youtube channel

About Pitch3D 

]]> 3DHEALS Buzzsprout-18116515 Sat, 01 Nov 2025 17:00:00 -0400 707 ChatGPT, intelligence, education, technology, productivity, AI, revolution, humanity 97 full false Episode #96 | The Future of Surgical Digital Twin with Gilly Yildirim (CEO, Vent Creativity) Episode #96 | The Future of Surgical Digital Twin with Gilly Yildirim (CEO, Vent Creativity) How well do we really understand the body? For decades, surgeons have relied on static scans and flat 2D models to plan procedures. Gilly Yildirim believes it’s time to expand our view to more dimensions. As founder and CEO of Vent Creativity, he is bringing together point clouds, digital twins, and physics-based AI to capture movement with a level of precision that static imaging is far from.

In conversation with Jenny Chen, Gilly Yildirim describes how his team built a platform that sees the body not as a collection of bones, but as a dynamic system of forces and interactions. Their software models the physics of ligaments, cartilage, and bone to predict how a patient’s knee will behave before surgery even begins. The goal is to give surgeons a more clear and reliable picture of what they’re working with.

Yildirim shares the thinking that shaped his company’s approach. The team’s goal wasn’t to design a product, but to build a service that integrates into real clinical practice. Vent’s technology includes Minerva, an adaptive AI engine trained on real anatomical data. It powers Hermes, an FDA-cleared knee planning tool, and inVENT, a cloud platform that lets surgeons explore patient-specific digital twins in full 3D.

Gilly Yildirim has 20 years of experience in orthopedics, so he has unique understanding of the clinical and technical sides of surgical innovation. He discusses how biomechanics, imaging physics, and computational modeling converge within Vent’s framework to create accurate, reproducible results. The same methods used to map a knee could soon extend to hips, shoulders, cardiac systems, and even to full-body digital twins that integrate data across multiple organs and modalities. His work points toward a future where medical planning is not based on snapshots, but on simulations that mirror the patient’s unique physiology.

This episode offers a deep, imaginative look at how AI, physics, and human creativity are coming together to build the next generation of surgical intelligence.

Send us Fan Mail

Support the show

Subscribe to our premium version and support the show. 

Follow us:
Twitter 
Instagram
Linkedin
3DHEALS Website
Facebook
Facebook Group
Youtube channel

About Pitch3D 

]]> How well do we really understand the body? For decades, surgeons have relied on static scans and flat 2D models to plan procedures. Gilly Yildirim believes it’s time to expand our view to more dimensions. As founder and CEO of Vent Creativity, he is bringing together point clouds, digital twins, and physics-based AI to capture movement with a level of precision that static imaging is far from.

In conversation with Jenny Chen, Gilly Yildirim describes how his team built a platform that sees the body not as a collection of bones, but as a dynamic system of forces and interactions. Their software models the physics of ligaments, cartilage, and bone to predict how a patient’s knee will behave before surgery even begins. The goal is to give surgeons a more clear and reliable picture of what they’re working with.

Yildirim shares the thinking that shaped his company’s approach. The team’s goal wasn’t to design a product, but to build a service that integrates into real clinical practice. Vent’s technology includes Minerva, an adaptive AI engine trained on real anatomical data. It powers Hermes, an FDA-cleared knee planning tool, and inVENT, a cloud platform that lets surgeons explore patient-specific digital twins in full 3D.

Gilly Yildirim has 20 years of experience in orthopedics, so he has unique understanding of the clinical and technical sides of surgical innovation. He discusses how biomechanics, imaging physics, and computational modeling converge within Vent’s framework to create accurate, reproducible results. The same methods used to map a knee could soon extend to hips, shoulders, cardiac systems, and even to full-body digital twins that integrate data across multiple organs and modalities. His work points toward a future where medical planning is not based on snapshots, but on simulations that mirror the patient’s unique physiology.

This episode offers a deep, imaginative look at how AI, physics, and human creativity are coming together to build the next generation of surgical intelligence.

Send us Fan Mail

Support the show

Subscribe to our premium version and support the show. 

Follow us:
Twitter 
Instagram
Linkedin
3DHEALS Website
Facebook
Facebook Group
Youtube channel

About Pitch3D 

]]> 3DHEALS Buzzsprout-18037527 Thu, 30 Oct 2025 13:00:00 -0400 4424 96 full false Episode #95 | Microfluidics & Additive Innovation with Paul Marshall Episode #95 | Microfluidics & Additive Innovation with Paul Marshall Microfluidics has long promised to reshape diagnostics, drug discovery, and laboratory science. Microfluidics is about manipulating how tiny amounts of liquid move through channels no wider than a human hair; a "lab on a chip" diagnostic. Now imagine being able to 3D print those channels instead of painstakingly etching them. Paul Marshall, CEO of Rapid Fluidics, is working to improve the norm by applying additive manufacturing to the design and production of microfluidic systems.

In this episode, Jenny Chen speaks with Marshall about how 3D printing enables fluidic devices with architectures that cannot be produced through conventional techniques. Traditional fabrication locks researchers into rigid patterns and flat geometries. Paul's work extends beyond basic microfluidics. 

His team creates remarkably detailed anatomical models by converting medical imaging data into functional vascular systems that mimic human biology. These models provide alternatives to animal testing and training platforms for medical procedures. They've also worked on embedding electronics directly into microfluidic devices, creating "smart" systems that can measure biological changes in real-time. Their work clearly demonstrates the potential of infusing engineering precision with scientific imagination.

Paul Marshall reflects on the growth of his career as a founder by detailing the progression from experimental prototypes to a growing enterprise serving research communities. Marshall launched this venture at the beginning of the COVID-19 pandemic, a seemingly unpromising time to start a business. However, as diagnostic companies pivoted to develop coronavirus tests, the demand for rapid prototyping exploded. Now five years later, Rapid Fluidics serves global healthcare giants from their base in Newcastle, England, while planning expansion to the United States. 

This conversation offers a perspective on microfluidics that goes beyond the traditional. If you’ve ever wondered how big breakthroughs emerge from small scales, this episode makes the case that the tiniest channels can carry some of the most exciting ideas.

Send us Fan Mail

Support the show

Subscribe to our premium version and support the show. 

Follow us:
Twitter 
Instagram
Linkedin
3DHEALS Website
Facebook
Facebook Group
Youtube channel

About Pitch3D 

]]> Microfluidics has long promised to reshape diagnostics, drug discovery, and laboratory science. Microfluidics is about manipulating how tiny amounts of liquid move through channels no wider than a human hair; a "lab on a chip" diagnostic. Now imagine being able to 3D print those channels instead of painstakingly etching them. Paul Marshall, CEO of Rapid Fluidics, is working to improve the norm by applying additive manufacturing to the design and production of microfluidic systems.

In this episode, Jenny Chen speaks with Marshall about how 3D printing enables fluidic devices with architectures that cannot be produced through conventional techniques. Traditional fabrication locks researchers into rigid patterns and flat geometries. Paul's work extends beyond basic microfluidics. 

His team creates remarkably detailed anatomical models by converting medical imaging data into functional vascular systems that mimic human biology. These models provide alternatives to animal testing and training platforms for medical procedures. They've also worked on embedding electronics directly into microfluidic devices, creating "smart" systems that can measure biological changes in real-time. Their work clearly demonstrates the potential of infusing engineering precision with scientific imagination.

Paul Marshall reflects on the growth of his career as a founder by detailing the progression from experimental prototypes to a growing enterprise serving research communities. Marshall launched this venture at the beginning of the COVID-19 pandemic, a seemingly unpromising time to start a business. However, as diagnostic companies pivoted to develop coronavirus tests, the demand for rapid prototyping exploded. Now five years later, Rapid Fluidics serves global healthcare giants from their base in Newcastle, England, while planning expansion to the United States. 

This conversation offers a perspective on microfluidics that goes beyond the traditional. If you’ve ever wondered how big breakthroughs emerge from small scales, this episode makes the case that the tiniest channels can carry some of the most exciting ideas.

Send us Fan Mail

Support the show

Subscribe to our premium version and support the show. 

Follow us:
Twitter 
Instagram
Linkedin
3DHEALS Website
Facebook
Facebook Group
Youtube channel

About Pitch3D 

]]> 3DHEALS Buzzsprout-17883282 Fri, 26 Sep 2025 00:00:00 -0400 3668 95 full false Episode #93 | 3D Design & Geometric Intelligence with Elissa Ross Episode #93 | 3D Design & Geometric Intelligence with Elissa Ross What happens when advanced mathematics meets manufacturing? The result is a new way of creating products that range from record-breaking running shoes to life-changing medical devices.

In this episode, we sit down with Elissa Ross, mathematician and CEO of Metafold 3D, to explore how her company is using mathematics to reshape design and manufacturing. Metafold’s platform is built on geometric intelligence which is her company's novel approach that transforms shapes into data that can be analyzed and improved. Instead of simply representing objects the way traditional CAD software does this method allows engineers to simulate and optimize designs with greater speed and accuracy.

At the core of this approach is implicit modeling with signed distance functions. While it may sound highly abstract, it has very practical applications. This technique allows manufacturers can run thousands of simulations in the time it would normally take to analyze a single design. The result is shorter development cycles and products that perform better in the real world.

Ross also reflects on her journey building Metafold, from its early focus on 3D printing to its current role serving major industries. She explains how their API-first platform gives customers the flexibility to solve specific challenges, such as analyzing tolerances, reusing similar parts, or predicting how designs will hold up under different conditions.

Whether you are a designer, an engineer, or simply curious about how mathematics is shaping the technologies around us, this episode offers a thoughtful look at the future of manufacturing intelligence.


Shownotes: Check back soon

Podcast Engineer: Faith Fernandes

Send us Fan Mail

Support the show

Subscribe to our premium version and support the show. 

Follow us:
Twitter 
Instagram
Linkedin
3DHEALS Website
Facebook
Facebook Group
Youtube channel

About Pitch3D 

]]> What happens when advanced mathematics meets manufacturing? The result is a new way of creating products that range from record-breaking running shoes to life-changing medical devices.

In this episode, we sit down with Elissa Ross, mathematician and CEO of Metafold 3D, to explore how her company is using mathematics to reshape design and manufacturing. Metafold’s platform is built on geometric intelligence which is her company's novel approach that transforms shapes into data that can be analyzed and improved. Instead of simply representing objects the way traditional CAD software does this method allows engineers to simulate and optimize designs with greater speed and accuracy.

At the core of this approach is implicit modeling with signed distance functions. While it may sound highly abstract, it has very practical applications. This technique allows manufacturers can run thousands of simulations in the time it would normally take to analyze a single design. The result is shorter development cycles and products that perform better in the real world.

Ross also reflects on her journey building Metafold, from its early focus on 3D printing to its current role serving major industries. She explains how their API-first platform gives customers the flexibility to solve specific challenges, such as analyzing tolerances, reusing similar parts, or predicting how designs will hold up under different conditions.

Whether you are a designer, an engineer, or simply curious about how mathematics is shaping the technologies around us, this episode offers a thoughtful look at the future of manufacturing intelligence.


Shownotes: Check back soon

Podcast Engineer: Faith Fernandes

Send us Fan Mail

Support the show

Subscribe to our premium version and support the show. 

Follow us:
Twitter 
Instagram
Linkedin
3DHEALS Website
Facebook
Facebook Group
Youtube channel

About Pitch3D 

]]> 3DHEALS Buzzsprout-17810285 Fri, 12 Sep 2025 16:00:00 -0400 3754 93 full false Episode #92 | Nanochon: Joint Repair Layer by Layer Episode #92 | Nanochon: Joint Repair Layer by Layer Cartilage injuries sideline millions every year, yet current treatments often fail to restore long-term function. In this episode, Dr. Nathan Castro and Dr. Ben Holmes, co-founders of Nanochon, explain how they are tackling this challenge with a 3D-printed implant designed not only to replace damaged tissue but to help it regrow. What began as a collaboration in a graduate lab has grown into a company now preparing for its first human clinical trial.

Their journey began at George Washington University in Dr. Grace Zhong’s tissue engineering lab, where the freedom to explore outside of strict grant-funded projects encouraged bold experimentation. Nathan even purchased specialized materials with his own money to expedite early tests. That investment in curiosity became the foundation for a technology that could change how orthopedic surgeons treat cartilage damage.

Nanochon’s implant blends strength with biology. It pairs a smooth articular surface with a porous lattice that integrates directly with surrounding tissue. Traditional approaches, Nathan explains, can be “like filling a pothole with jelly.” By contrast, their device provides stability without the need for sutures or pins. Despite being less than half the thickness of conventional implants, it requires two to three times more force to dislodge, which may result in shorter recovery times for patients.

From there, the company advanced step by step. They began with small animal studies in rats, progressed to goats, and finally proved the implant’s strength and integration in horses. These results not only built regulatory confidence but also convinced investors. With Health Canada’s approval for its first-in-human trial, Nanochon stands on the edge of translating a decade of persistence into clinical impact.

Ben and Nathan also reveal the realities of building a medical device startup, including raising funds during tight markets, meeting ISO 13485 quality standards, and learning to manage external contractors. This conversation is a rare look behind the curtain of medtech entrepreneurship. It shows how innovation happens in steady layers, built one on top of another, much like 3D printing itself.

Shownotes

Podcast Engineer: Faith Fernandes



Send us Fan Mail

Support the show

Subscribe to our premium version and support the show. 

Follow us:
Twitter 
Instagram
Linkedin
3DHEALS Website
Facebook
Facebook Group
Youtube channel

About Pitch3D 

]]> Cartilage injuries sideline millions every year, yet current treatments often fail to restore long-term function. In this episode, Dr. Nathan Castro and Dr. Ben Holmes, co-founders of Nanochon, explain how they are tackling this challenge with a 3D-printed implant designed not only to replace damaged tissue but to help it regrow. What began as a collaboration in a graduate lab has grown into a company now preparing for its first human clinical trial.

Their journey began at George Washington University in Dr. Grace Zhong’s tissue engineering lab, where the freedom to explore outside of strict grant-funded projects encouraged bold experimentation. Nathan even purchased specialized materials with his own money to expedite early tests. That investment in curiosity became the foundation for a technology that could change how orthopedic surgeons treat cartilage damage.

Nanochon’s implant blends strength with biology. It pairs a smooth articular surface with a porous lattice that integrates directly with surrounding tissue. Traditional approaches, Nathan explains, can be “like filling a pothole with jelly.” By contrast, their device provides stability without the need for sutures or pins. Despite being less than half the thickness of conventional implants, it requires two to three times more force to dislodge, which may result in shorter recovery times for patients.

From there, the company advanced step by step. They began with small animal studies in rats, progressed to goats, and finally proved the implant’s strength and integration in horses. These results not only built regulatory confidence but also convinced investors. With Health Canada’s approval for its first-in-human trial, Nanochon stands on the edge of translating a decade of persistence into clinical impact.

Ben and Nathan also reveal the realities of building a medical device startup, including raising funds during tight markets, meeting ISO 13485 quality standards, and learning to manage external contractors. This conversation is a rare look behind the curtain of medtech entrepreneurship. It shows how innovation happens in steady layers, built one on top of another, much like 3D printing itself.

Shownotes

Podcast Engineer: Faith Fernandes



Send us Fan Mail

Support the show

Subscribe to our premium version and support the show. 

Follow us:
Twitter 
Instagram
Linkedin
3DHEALS Website
Facebook
Facebook Group
Youtube channel

About Pitch3D 

]]> 3DHEALS Buzzsprout-17732929 Wed, 27 Aug 2025 00:00:00 -0400 4188 92 full false Episode #90 | 3D Printing Across Decades with Lee Dockstader Episode #90 | 3D Printing Across Decades with Lee Dockstader Lee Dockstader takes us on a fascinating journey through the commercialization of 3D printing in healthcare, drawing from his decades of experience with industry giants like HP and 3D Systems. Dockstader is one of the major pioneers of the 3D printing revolution that helped transform medical applications today.

The conversation takes us behind the curtain of industry-defining moments few people know about. One is the story of Invisalign. Today it’s a household name, but in its early years Align Technology struggled to survive. Orthodontists resisted the innovation, and for nearly a decade the company failed to turn a profit. It was only when dentists began to embrace the technology that it found its footing. We explore why some healthcare segments adopt 3D printing rapidly while others move at glacial pace, and the fascinating business dynamics that determine success beyond just having superior technology.

Dockstader then goes on to give his account of the hearing aid industry's rapid transformation. Unlike dental's decades-long evolution, hearing aid manufacturing converted entirely to 3D printing within just five years in the early 2000s. The perfect storm of new scanning technology, specialized resins, and advanced printers led to dramatic improvements: reducing remake rates from 20% to 5% and transforming a craft that took a year to master into a skill learnable in days. With five companies controlling 80% of the market, once one adopted the technology, competitors had no choice but follow.

Looking toward the future, Dockstader shares his surprise that 3D printed eyewear hasn't yet achieved mainstream adoption despite its obvious benefits. With conventional frames offering limited sizing options despite high tooling costs, 3D printing could provide perfectly fitted frames for diverse facial structures at competitive prices. 

As he looks back on his career, Lee Dockstader leaves listeners with a clear message. Persistence pays off, and finding the right champions within an industry can be the key to turning groundbreaking ideas into world-changing realities.


Stay tuned for show notes with relevant links and resources.


Sound Engineer: Faith Fernandes 

Send us Fan Mail

Support the show

Subscribe to our premium version and support the show. 

Follow us:
Twitter 
Instagram
Linkedin
3DHEALS Website
Facebook
Facebook Group
Youtube channel

About Pitch3D 

]]> Lee Dockstader takes us on a fascinating journey through the commercialization of 3D printing in healthcare, drawing from his decades of experience with industry giants like HP and 3D Systems. Dockstader is one of the major pioneers of the 3D printing revolution that helped transform medical applications today.

The conversation takes us behind the curtain of industry-defining moments few people know about. One is the story of Invisalign. Today it’s a household name, but in its early years Align Technology struggled to survive. Orthodontists resisted the innovation, and for nearly a decade the company failed to turn a profit. It was only when dentists began to embrace the technology that it found its footing. We explore why some healthcare segments adopt 3D printing rapidly while others move at glacial pace, and the fascinating business dynamics that determine success beyond just having superior technology.

Dockstader then goes on to give his account of the hearing aid industry's rapid transformation. Unlike dental's decades-long evolution, hearing aid manufacturing converted entirely to 3D printing within just five years in the early 2000s. The perfect storm of new scanning technology, specialized resins, and advanced printers led to dramatic improvements: reducing remake rates from 20% to 5% and transforming a craft that took a year to master into a skill learnable in days. With five companies controlling 80% of the market, once one adopted the technology, competitors had no choice but follow.

Looking toward the future, Dockstader shares his surprise that 3D printed eyewear hasn't yet achieved mainstream adoption despite its obvious benefits. With conventional frames offering limited sizing options despite high tooling costs, 3D printing could provide perfectly fitted frames for diverse facial structures at competitive prices. 

As he looks back on his career, Lee Dockstader leaves listeners with a clear message. Persistence pays off, and finding the right champions within an industry can be the key to turning groundbreaking ideas into world-changing realities.


Stay tuned for show notes with relevant links and resources.


Sound Engineer: Faith Fernandes 

Send us Fan Mail

Support the show

Subscribe to our premium version and support the show. 

Follow us:
Twitter 
Instagram
Linkedin
3DHEALS Website
Facebook
Facebook Group
Youtube channel

About Pitch3D 

]]> 3DHEALS Buzzsprout-17650775 Thu, 14 Aug 2025 19:00:00 -0400 3956 90 full false Episode #88 | Shaping Veterinary Medicine in 3D with Dr. Bill Oxley Episode #88 | Shaping Veterinary Medicine in 3D with Dr. Bill Oxley What happens when cutting-edge technology meets veterinary expertise? Precision, innovation, and better outcomes for our four-legged family members. 

Dr. Bill Oxley, a prominent figure in veterinary orthopaedics, walks us through the evolving world of 3D-guided veterinary surgery. With years of surgical experience behind him, Dr. Oxley began to question the limits of traditional planning methods. Complex bone deformities that looked manageable on initially often became challenges in the operating room. The tools weren’t the problem. The planning was. His solution? Bringing veterinary orthopedics into the three-dimensional world through advanced imaging, computer-aided design, and 3D printing.

Dr. Oxley's approach helped 3D planning completely change how we asses deformities for the better. The shift from struggling with conventional 2D planning to creating precise surgical guides. These custom guides allow surgeons to make exactly the right cuts in exactly the right places, dramatically improving outcomes for patients with complex orthopedic conditions. The emotional highlight comes when he shares the story of a Great Dane with bone cancer who, thanks to this technology, went from facing amputation to running joyfully on the beach just weeks after reconstructive surgery.

Beyond the technical aspects, we explore the business challenges of building Vet3D, the global adoption of these techniques, and how pet insurance dramatically impacts which animals can access these life-changing procedures. For pet owners, this conversation offers invaluable insights into what's possible when your beloved companion faces orthopedic challenges.

Curious about the cutting edge of veterinary care? Want to understand how technology is expanding what's possible for our pets? This episode will leave you amazed at how far veterinary medicine has come and hopeful about where it's heading. Connect with Dr. Bill directly at bill@vet3d.co.uk to learn more about these groundbreaking approaches.

Show notes, photo gallery, resource links: Please see our show notes here.

Sound Engineer: Faith Fernandes 

Send us Fan Mail

Support the show

Subscribe to our premium version and support the show. 

Follow us:
Twitter 
Instagram
Linkedin
3DHEALS Website
Facebook
Facebook Group
Youtube channel

About Pitch3D 

]]> What happens when cutting-edge technology meets veterinary expertise? Precision, innovation, and better outcomes for our four-legged family members. 

Dr. Bill Oxley, a prominent figure in veterinary orthopaedics, walks us through the evolving world of 3D-guided veterinary surgery. With years of surgical experience behind him, Dr. Oxley began to question the limits of traditional planning methods. Complex bone deformities that looked manageable on initially often became challenges in the operating room. The tools weren’t the problem. The planning was. His solution? Bringing veterinary orthopedics into the three-dimensional world through advanced imaging, computer-aided design, and 3D printing.

Dr. Oxley's approach helped 3D planning completely change how we asses deformities for the better. The shift from struggling with conventional 2D planning to creating precise surgical guides. These custom guides allow surgeons to make exactly the right cuts in exactly the right places, dramatically improving outcomes for patients with complex orthopedic conditions. The emotional highlight comes when he shares the story of a Great Dane with bone cancer who, thanks to this technology, went from facing amputation to running joyfully on the beach just weeks after reconstructive surgery.

Beyond the technical aspects, we explore the business challenges of building Vet3D, the global adoption of these techniques, and how pet insurance dramatically impacts which animals can access these life-changing procedures. For pet owners, this conversation offers invaluable insights into what's possible when your beloved companion faces orthopedic challenges.

Curious about the cutting edge of veterinary care? Want to understand how technology is expanding what's possible for our pets? This episode will leave you amazed at how far veterinary medicine has come and hopeful about where it's heading. Connect with Dr. Bill directly at bill@vet3d.co.uk to learn more about these groundbreaking approaches.

Show notes, photo gallery, resource links: Please see our show notes here.

Sound Engineer: Faith Fernandes 

Send us Fan Mail

Support the show

Subscribe to our premium version and support the show. 

Follow us:
Twitter 
Instagram
Linkedin
3DHEALS Website
Facebook
Facebook Group
Youtube channel

About Pitch3D 

]]> 3DHEALS Buzzsprout-17515073 Thu, 17 Jul 2025 13:00:00 -0400 3559 88 full false Episode #87 | Lattice News Summary: The Bioprinting Revolution & More Episode #87 | Lattice News Summary: The Bioprinting Revolution & More This is an AI-generated audio version of the news section of the Lattice Newsletter. You can find the full newsletter, including a list of recent healthcare 3D printing and bioprinting news here. 

Full Lattice Newsletter Archive.

Highlighted news this week:


• US Army developing field-deployable bioprinting labs for creating custom skin grafts in combat zones
• Stanford researchers designing organ-scale vascular trees for 3D-printed hearts 200 times faster than previous methods
• First patient treated with a bioengineered external liver (ELAP) for acute liver failure
• Researchers creating 3D bioprinted brain models that mimic real neural networks for studying Alzheimer's
• FDA-cleared monolithic full-color 3D printed dentures (Trudent) revolutionizing dental prosthetics
• New polymer blend for 3D printed medical devices kills 99.99999% of common bacteria
• World's first 3D-printed femur transplant in an 8-year-old child in Vietnam
• Healthcare systems bringing 3D printing capabilities directly into hospitals for point-of-care manufacturing
• Six key trends: hyper-personalization, point-of-care manufacturing, advanced materials, increased efficiency, addressing healthcare challenges, and regulatory progress



Send us Fan Mail

Support the show

Subscribe to our premium version and support the show. 

Follow us:
Twitter 
Instagram
Linkedin
3DHEALS Website
Facebook
Facebook Group
Youtube channel

About Pitch3D 

]]> This is an AI-generated audio version of the news section of the Lattice Newsletter. You can find the full newsletter, including a list of recent healthcare 3D printing and bioprinting news here. 

Full Lattice Newsletter Archive.

Highlighted news this week:


• US Army developing field-deployable bioprinting labs for creating custom skin grafts in combat zones
• Stanford researchers designing organ-scale vascular trees for 3D-printed hearts 200 times faster than previous methods
• First patient treated with a bioengineered external liver (ELAP) for acute liver failure
• Researchers creating 3D bioprinted brain models that mimic real neural networks for studying Alzheimer's
• FDA-cleared monolithic full-color 3D printed dentures (Trudent) revolutionizing dental prosthetics
• New polymer blend for 3D printed medical devices kills 99.99999% of common bacteria
• World's first 3D-printed femur transplant in an 8-year-old child in Vietnam
• Healthcare systems bringing 3D printing capabilities directly into hospitals for point-of-care manufacturing
• Six key trends: hyper-personalization, point-of-care manufacturing, advanced materials, increased efficiency, addressing healthcare challenges, and regulatory progress



Send us Fan Mail

Support the show

Subscribe to our premium version and support the show. 

Follow us:
Twitter 
Instagram
Linkedin
3DHEALS Website
Facebook
Facebook Group
Youtube channel

About Pitch3D 

]]> 3DHEALS Buzzsprout-17458055 Thu, 10 Jul 2025 00:00:00 -0400 1429 full false Episode #86 | AI's Vital Role in Medical 3D Printing (Virtual Event Recording) Episode #86 | AI's Vital Role in Medical 3D Printing (Virtual Event Recording) Artificial intelligence is transforming medical 3D printing and bioprinting. In this virtual event, hear from a panel of experts from across the globe. Our speakers showcase the practical applications of AI in creating personalized medical solutions that were previously impossible.

One size does not fit all. William Jung, Business Development Director of FITme in South Korea, explains how AI-driven customized silicone implants are revolutionizing cosmetic and reconstructive surgery. Using a design screening engine that reduces design time from hours to minutes, FITme’s technology has supported over 30,000 surgical cases and captured 85% of the Korean market.

At the National University of Singapore, Dr. Gopu Sriram explores dental applications of 3D bioprinting. He discusses how an AI-optimized bioprinting process allow for the biofabrication of personalized gum tissue constructs. Gum disease is a worldwide public health burden that affects almost half adults over age thirty. This solution not only addresses these patients, but dramatically accelerates experimental timelines.

Dr. Gregory Hayes brings in the business perspective and shares how EOS Additive Minds is implementing AI across multiple fronts to democratize access to additive manufacturing. Their systems incorporate advanced monitoring tools capable of making real-time adjustments during printing. This allows medical professionals to stay focused on patient outcomes over technical issues.

Focusing on women's health, Aye Nyein San from Cosm Medical shared how their AI-powered digital gynecologic devices are giving women their lives back, with patients describing their products as "magical" and "life-changing."

What makes this event so compelling to listen to is how our speakers illustrate AI’s ability to break down long-standing barriers to 3D printing adoption. By automating complex design decisions and enhancing process reliability, AI is turning specialized, expertise-heavy workflows into scalable, patient-centered solutions.

Ready to explore how AI and 3D printing could effect your medical practice or research? Subscribe to our podcast for more insights into this rapidly evolving field, and join our community of innovators.


Shownotes: https://3dheals.com/event-recap-artificial-intelligence-updates-for-3d-printing-and-bioprinting/

Podcast Engineer: Faith Fernandes

Send us Fan Mail

Support the show

Subscribe to our premium version and support the show. 

Follow us:
Twitter 
Instagram
Linkedin
3DHEALS Website
Facebook
Facebook Group
Youtube channel

About Pitch3D 

]]> Artificial intelligence is transforming medical 3D printing and bioprinting. In this virtual event, hear from a panel of experts from across the globe. Our speakers showcase the practical applications of AI in creating personalized medical solutions that were previously impossible.

One size does not fit all. William Jung, Business Development Director of FITme in South Korea, explains how AI-driven customized silicone implants are revolutionizing cosmetic and reconstructive surgery. Using a design screening engine that reduces design time from hours to minutes, FITme’s technology has supported over 30,000 surgical cases and captured 85% of the Korean market.

At the National University of Singapore, Dr. Gopu Sriram explores dental applications of 3D bioprinting. He discusses how an AI-optimized bioprinting process allow for the biofabrication of personalized gum tissue constructs. Gum disease is a worldwide public health burden that affects almost half adults over age thirty. This solution not only addresses these patients, but dramatically accelerates experimental timelines.

Dr. Gregory Hayes brings in the business perspective and shares how EOS Additive Minds is implementing AI across multiple fronts to democratize access to additive manufacturing. Their systems incorporate advanced monitoring tools capable of making real-time adjustments during printing. This allows medical professionals to stay focused on patient outcomes over technical issues.

Focusing on women's health, Aye Nyein San from Cosm Medical shared how their AI-powered digital gynecologic devices are giving women their lives back, with patients describing their products as "magical" and "life-changing."

What makes this event so compelling to listen to is how our speakers illustrate AI’s ability to break down long-standing barriers to 3D printing adoption. By automating complex design decisions and enhancing process reliability, AI is turning specialized, expertise-heavy workflows into scalable, patient-centered solutions.

Ready to explore how AI and 3D printing could effect your medical practice or research? Subscribe to our podcast for more insights into this rapidly evolving field, and join our community of innovators.


Shownotes: https://3dheals.com/event-recap-artificial-intelligence-updates-for-3d-printing-and-bioprinting/

Podcast Engineer: Faith Fernandes

Send us Fan Mail

Support the show

Subscribe to our premium version and support the show. 

Follow us:
Twitter 
Instagram
Linkedin
3DHEALS Website
Facebook
Facebook Group
Youtube channel

About Pitch3D 

]]> 3DHEALS Buzzsprout-17385879 Sun, 29 Jun 2025 16:00:00 -0400 6519 86 full false Episode #85 | Jetting the Impossible: Ben Hartkopp on Printing Ultra-Viscous Materials Episode #85 | Jetting the Impossible: Ben Hartkopp on Printing Ultra-Viscous Materials Printhead technology may not sound revolutionary, but what if it could radically transform the way we manufacture everything from electric motors to medical implants? That's exactly what Ben Harkoff and his team at Quantica have achieved with their breakthrough inkjet system that can handle materials 10-20 times more viscous than any conventional technology.

Starting in 2018 with a simple goal of printing electronics, Ben's team became frustrated when every existing printhead failed spectacularly when trying to eject viscous resins. Their solution? Design something completely new using piezo crystal actuators and compliant mechanisms that could amplify deformation. This innovation unlocked the ability to print materials with viscosities ranging from 250 millipascal-seconds at operating temperatures to 15,000 millipascal-seconds at room temperature, opening up vast new possibilities for manufacturing.

What's particularly fascinating is Quantica's journey from 3D printing visionaries to practical problem-solvers. As Ben candidly shares, the company discovered its most immediate impact wasn't in creating complete 3D-printed products but in revolutionizing existing manufacturing processes. Their technology now enables precision deposition of adhesives for e-motors, replacing inefficient dispensing methods and potentially improving motor efficiency. They've validated the printing of true platinum-catalyzed silicone (SYLGARD 184) without additives—a breakthrough for medical applications—and are exploring how viscoelastic materials enhance cell viability for bioprinting applications.

Whether you're interested in manufacturing technology, materials science, or how startups navigate the challenging path from invention to commercial success, this conversation offers valuable insights. Ben's advice for aspiring inventors? "Become obsessed and become an expert in research... train your attention span... and learn about politics, because part of the job is not only the technical depth but also dealing with people." Listen now to discover how printing the unprintable is creating entirely new possibilities across industries.


Complete show notes with references

Send us Fan Mail

Support the show

Subscribe to our premium version and support the show. 

Follow us:
Twitter 
Instagram
Linkedin
3DHEALS Website
Facebook
Facebook Group
Youtube channel

About Pitch3D 

]]> Printhead technology may not sound revolutionary, but what if it could radically transform the way we manufacture everything from electric motors to medical implants? That's exactly what Ben Harkoff and his team at Quantica have achieved with their breakthrough inkjet system that can handle materials 10-20 times more viscous than any conventional technology.

Starting in 2018 with a simple goal of printing electronics, Ben's team became frustrated when every existing printhead failed spectacularly when trying to eject viscous resins. Their solution? Design something completely new using piezo crystal actuators and compliant mechanisms that could amplify deformation. This innovation unlocked the ability to print materials with viscosities ranging from 250 millipascal-seconds at operating temperatures to 15,000 millipascal-seconds at room temperature, opening up vast new possibilities for manufacturing.

What's particularly fascinating is Quantica's journey from 3D printing visionaries to practical problem-solvers. As Ben candidly shares, the company discovered its most immediate impact wasn't in creating complete 3D-printed products but in revolutionizing existing manufacturing processes. Their technology now enables precision deposition of adhesives for e-motors, replacing inefficient dispensing methods and potentially improving motor efficiency. They've validated the printing of true platinum-catalyzed silicone (SYLGARD 184) without additives—a breakthrough for medical applications—and are exploring how viscoelastic materials enhance cell viability for bioprinting applications.

Whether you're interested in manufacturing technology, materials science, or how startups navigate the challenging path from invention to commercial success, this conversation offers valuable insights. Ben's advice for aspiring inventors? "Become obsessed and become an expert in research... train your attention span... and learn about politics, because part of the job is not only the technical depth but also dealing with people." Listen now to discover how printing the unprintable is creating entirely new possibilities across industries.


Complete show notes with references

Send us Fan Mail

Support the show

Subscribe to our premium version and support the show. 

Follow us:
Twitter 
Instagram
Linkedin
3DHEALS Website
Facebook
Facebook Group
Youtube channel

About Pitch3D 

]]> 3DHEALS Buzzsprout-17260050 Sun, 01 Jun 2025 15:00:00 -0400 1374 85 full false Episode #84 | Tuan Tranpham On 3D Printing Mega-Trends Episode #84 | Tuan Tranpham On 3D Printing Mega-Trends Tuan Tranpham shares his extraordinary journey from Vietnamese refugee to 3D printing industry leader, offering unique insights on industry evolution, technological innovation, and future trends. His global perspective bridges Eastern and Western manufacturing approaches while highlighting continuous carbon fiber printing opportunities and microfactory development.

  • Vietnamese refugee turned global 3D printing leader
  • 3D printing in 2003, after Z Corp 
  • The Journey: 3D Systems, Desktop Metal, Anisoprint
  • Industry consolidation and integration strategies
  • Carbon fiber 3D printing for aerospace and defense
  • Highlights China’s rapid rise in 3D printing innovation
  • AI, robotics, and AM will enable portable microfactories
  • Built a personal brand on LinkedIn
  • Innovation is key to staying competitive
  • Bravery and generosity in career growth


Show notes

Send us Fan Mail

Support the show

Subscribe to our premium version and support the show. 

Follow us:
Twitter 
Instagram
Linkedin
3DHEALS Website
Facebook
Facebook Group
Youtube channel

About Pitch3D 

]]> Tuan Tranpham shares his extraordinary journey from Vietnamese refugee to 3D printing industry leader, offering unique insights on industry evolution, technological innovation, and future trends. His global perspective bridges Eastern and Western manufacturing approaches while highlighting continuous carbon fiber printing opportunities and microfactory development.

  • Vietnamese refugee turned global 3D printing leader
  • 3D printing in 2003, after Z Corp 
  • The Journey: 3D Systems, Desktop Metal, Anisoprint
  • Industry consolidation and integration strategies
  • Carbon fiber 3D printing for aerospace and defense
  • Highlights China’s rapid rise in 3D printing innovation
  • AI, robotics, and AM will enable portable microfactories
  • Built a personal brand on LinkedIn
  • Innovation is key to staying competitive
  • Bravery and generosity in career growth


Show notes

Send us Fan Mail

Support the show

Subscribe to our premium version and support the show. 

Follow us:
Twitter 
Instagram
Linkedin
3DHEALS Website
Facebook
Facebook Group
Youtube channel

About Pitch3D 

]]> 3DHEALS Buzzsprout-17121087 Thu, 08 May 2025 01:00:00 -0400 3535 84 full false Episode #83 | Ceramics, Conferences, and the Future of 3D Printing With Craig Rosenblum Episode #83 | Ceramics, Conferences, and the Future of 3D Printing With Craig Rosenblum When EOS president Glynn Fletcher declared "3D printing is cool, but cool is not a business model" at Rapid TCT 2025, he captured the evolution across the additive manufacturing landscape. In this eye-opening conversation with Craig Rosenblum, president of Himed, we explore how the industry matures beyond technological demonstrations toward practical, sustainable applications.

Craig brings a unique perspective as both a materials science expert and the leader of a 35-year-old biomaterials company (Himed) that has adapted to incorporate 3D printing into its portfolio. He walks us through the shifts he observed at North America's largest 3D printing conference, where the atmosphere has noticeably changed from previous years' technology showcases to focused discussions on industry-specific solutions.

The conversation reveals fascinating developments, from the MIT startup creating "gravity-defying" materials through Rapid Liquid Printing in hydrogels to the reality behind AI buzzwords in additive manufacturing. We discuss how the ecosystem surrounding 3D printing is expanding, with increased participation from supporting industries like materials suppliers and testing laboratories, who recognize their crucial role in advancing the technology.

Perhaps most compelling is the emphasis on collaboration over competition. As Stratasys CEO Yoav Zeif noted, "The competition is status quo" - a recognition that advancing additive manufacturing requires collective effort across sectors rather than siloed approaches. This collaborative mindset particularly resonates in healthcare applications, where improved patient outcomes provide a powerful shared purpose.

Whether you're a 3D printing professional, healthcare innovator, or curious about how manufacturing is evolving, this conversation offers valuable insights into an industry at an inflection point - moving from what's possible to what's useful, from technological spectacle to sustainable transformation.

Send us Fan Mail

Support the show

Subscribe to our premium version and support the show. 

Follow us:
Twitter 
Instagram
Linkedin
3DHEALS Website
Facebook
Facebook Group
Youtube channel

About Pitch3D 

]]> When EOS president Glynn Fletcher declared "3D printing is cool, but cool is not a business model" at Rapid TCT 2025, he captured the evolution across the additive manufacturing landscape. In this eye-opening conversation with Craig Rosenblum, president of Himed, we explore how the industry matures beyond technological demonstrations toward practical, sustainable applications.

Craig brings a unique perspective as both a materials science expert and the leader of a 35-year-old biomaterials company (Himed) that has adapted to incorporate 3D printing into its portfolio. He walks us through the shifts he observed at North America's largest 3D printing conference, where the atmosphere has noticeably changed from previous years' technology showcases to focused discussions on industry-specific solutions.

The conversation reveals fascinating developments, from the MIT startup creating "gravity-defying" materials through Rapid Liquid Printing in hydrogels to the reality behind AI buzzwords in additive manufacturing. We discuss how the ecosystem surrounding 3D printing is expanding, with increased participation from supporting industries like materials suppliers and testing laboratories, who recognize their crucial role in advancing the technology.

Perhaps most compelling is the emphasis on collaboration over competition. As Stratasys CEO Yoav Zeif noted, "The competition is status quo" - a recognition that advancing additive manufacturing requires collective effort across sectors rather than siloed approaches. This collaborative mindset particularly resonates in healthcare applications, where improved patient outcomes provide a powerful shared purpose.

Whether you're a 3D printing professional, healthcare innovator, or curious about how manufacturing is evolving, this conversation offers valuable insights into an industry at an inflection point - moving from what's possible to what's useful, from technological spectacle to sustainable transformation.

Send us Fan Mail

Support the show

Subscribe to our premium version and support the show. 

Follow us:
Twitter 
Instagram
Linkedin
3DHEALS Website
Facebook
Facebook Group
Youtube channel

About Pitch3D 

]]> 3DHEALS Buzzsprout-17083875 Fri, 02 May 2025 15:00:00 -0400 2971 83 full false Episode #81 | From J&J to the Future: Sam Onukuri's 30-Year Adventure in 3D Printed Medical Devices Episode #81 | From J&J to the Future: Sam Onukuri's 30-Year Adventure in 3D Printed Medical Devices Sam Onukuri takes us through his remarkable 30-year journey at Johnson & Johnson, where he transformed the landscape of medical devices through pioneering work in 3D printing technology. As a material scientist who led the development of J&J's Center of Excellence for additive manufacturing, Sam offers rare insights into how a global healthcare giant approached innovation and personalized medicine.

The conversation reveals the fascinating evolution of medical 3D printing from basic prototyping to FDA-approved implants. Sam shares the story behind breakthrough products, such as the TrueMatch graft cage – a PCL-based, bioabsorbable scaffold for bone reconstruction that has dramatically improved patient outcomes. His candid assessment of where personalization succeeds (craniomaxillofacial implants) and where it falls short (knee replacements) provides a nuanced perspective rarely found in technology discussions.

We examine the unexpected challenges that have shaped the industry, including the complex regulatory landscape, the emergence of surgical robots, and the economic realities that have tempered some early expectations. Sam's firsthand experience with point-of-care printing initiatives and customized surgical instruments provides valuable lessons about striking a balance between innovation and practicality in healthcare settings.

Looking toward the future, Sam identifies promising frontiers, including bioprinting, advancements in materials science, and the integration of AI with 3D printing technologies. For students and professionals considering careers in this field, he emphasizes the importance of strong engineering fundamentals and experiencing both startup and corporate environments to develop a comprehensive skill set.

Whether you're a healthcare professional, engineer, investor, or simply curious about how medical innovation occurs, this conversation offers an authentic glimpse into the triumphs, setbacks, and unrealized dreams that continue to shape the future of personalized medicine and additive manufacturing.



Send us Fan Mail

Support the show

Subscribe to our premium version and support the show. 

Follow us:
Twitter 
Instagram
Linkedin
3DHEALS Website
Facebook
Facebook Group
Youtube channel

About Pitch3D 

]]> Sam Onukuri takes us through his remarkable 30-year journey at Johnson & Johnson, where he transformed the landscape of medical devices through pioneering work in 3D printing technology. As a material scientist who led the development of J&J's Center of Excellence for additive manufacturing, Sam offers rare insights into how a global healthcare giant approached innovation and personalized medicine.

The conversation reveals the fascinating evolution of medical 3D printing from basic prototyping to FDA-approved implants. Sam shares the story behind breakthrough products, such as the TrueMatch graft cage – a PCL-based, bioabsorbable scaffold for bone reconstruction that has dramatically improved patient outcomes. His candid assessment of where personalization succeeds (craniomaxillofacial implants) and where it falls short (knee replacements) provides a nuanced perspective rarely found in technology discussions.

We examine the unexpected challenges that have shaped the industry, including the complex regulatory landscape, the emergence of surgical robots, and the economic realities that have tempered some early expectations. Sam's firsthand experience with point-of-care printing initiatives and customized surgical instruments provides valuable lessons about striking a balance between innovation and practicality in healthcare settings.

Looking toward the future, Sam identifies promising frontiers, including bioprinting, advancements in materials science, and the integration of AI with 3D printing technologies. For students and professionals considering careers in this field, he emphasizes the importance of strong engineering fundamentals and experiencing both startup and corporate environments to develop a comprehensive skill set.

Whether you're a healthcare professional, engineer, investor, or simply curious about how medical innovation occurs, this conversation offers an authentic glimpse into the triumphs, setbacks, and unrealized dreams that continue to shape the future of personalized medicine and additive manufacturing.



Send us Fan Mail

Support the show

Subscribe to our premium version and support the show. 

Follow us:
Twitter 
Instagram
Linkedin
3DHEALS Website
Facebook
Facebook Group
Youtube channel

About Pitch3D 

]]> 3DHEALS Buzzsprout-16994546 Sat, 19 Apr 2025 17:00:00 -0400 4855 81 full false Episode #80 | Live from San Francisco: Innovation in 3D Printing & Bioprinting Episode #80 | Live from San Francisco: Innovation in 3D Printing & Bioprinting 3DHEALS kicked off its first in-person/hybrid event in 2025 in San Francisco, welcoming investors, entrepreneurs, and innovators in the space. The healthcare industry is transforming, driven by 3D printing and bioprinting technologies redefining patient care. This exclusive in-person hybrid event offered an opportunity to explore the latest advancements in custom prosthetics, implants, bioprinted tissues, and scaffolds.  The remarkable convergence of 3D printing and healthcare transforms medicine through customized solutions that weren't possible a decade ago. This episode brings together five leaders in the healthcare field who are harnessing additive manufacturing to solve real clinical problems and improve patient outcomes.

Summary:

  • 3D-printed spinal implants have evolved from simple titanium cages to sophisticated expandable devices that restore alignment and relieve nerve compression
  • Patient-specific radiation shields protect healthy tissue during cancer treatment, reducing devastating side effects like oral mucositis
  • Bioprinted organoids are creating human-derived testing platforms for drug discovery
  • 3D-printed trabecular metal structures are providing better bone integration for joint replacements
  • AR/VR integration with 3D printing is a robust tool for surgical planning, training, and patient education..
  • Evidence-based innovation remains critical, focusing on validated clinical problems rather than technology for technology's sake.
  • The shift toward ambulatory surgical centers drives demand for minimally invasive solutions that 3D printing can uniquely deliver.
  • Investment in medical 3D printing continues as clinical applications expand.

The experts emphasize that successful innovation must be evidence-based, addressing validated clinical problems rather than pursuing complexity for its own sake. The speakers agreed, "Just because it's complex doesn't mean it's better." This wisdom encapsulates the mindful approach needed as we continue exploring the vast potential of 3D printing in healthcare.


SUBSCRIBE to join us at future 3DHEALS conferences to connect with innovators and investors in the rapidly evolving field of 3D printing for healthcare applications.

Watch this event recording on demand.

Check out our blog for an in-depth analysis of the event!

Youtube Event Highlight Playlist.



Send us Fan Mail

Support the show

Subscribe to our premium version and support the show. 

Follow us:
Twitter 
Instagram
Linkedin
3DHEALS Website
Facebook
Facebook Group
Youtube channel

About Pitch3D 

]]> 3DHEALS kicked off its first in-person/hybrid event in 2025 in San Francisco, welcoming investors, entrepreneurs, and innovators in the space. The healthcare industry is transforming, driven by 3D printing and bioprinting technologies redefining patient care. This exclusive in-person hybrid event offered an opportunity to explore the latest advancements in custom prosthetics, implants, bioprinted tissues, and scaffolds.  The remarkable convergence of 3D printing and healthcare transforms medicine through customized solutions that weren't possible a decade ago. This episode brings together five leaders in the healthcare field who are harnessing additive manufacturing to solve real clinical problems and improve patient outcomes.

Summary:

  • 3D-printed spinal implants have evolved from simple titanium cages to sophisticated expandable devices that restore alignment and relieve nerve compression
  • Patient-specific radiation shields protect healthy tissue during cancer treatment, reducing devastating side effects like oral mucositis
  • Bioprinted organoids are creating human-derived testing platforms for drug discovery
  • 3D-printed trabecular metal structures are providing better bone integration for joint replacements
  • AR/VR integration with 3D printing is a robust tool for surgical planning, training, and patient education..
  • Evidence-based innovation remains critical, focusing on validated clinical problems rather than technology for technology's sake.
  • The shift toward ambulatory surgical centers drives demand for minimally invasive solutions that 3D printing can uniquely deliver.
  • Investment in medical 3D printing continues as clinical applications expand.

The experts emphasize that successful innovation must be evidence-based, addressing validated clinical problems rather than pursuing complexity for its own sake. The speakers agreed, "Just because it's complex doesn't mean it's better." This wisdom encapsulates the mindful approach needed as we continue exploring the vast potential of 3D printing in healthcare.


SUBSCRIBE to join us at future 3DHEALS conferences to connect with innovators and investors in the rapidly evolving field of 3D printing for healthcare applications.

Watch this event recording on demand.

Check out our blog for an in-depth analysis of the event!

Youtube Event Highlight Playlist.



Send us Fan Mail

Support the show

Subscribe to our premium version and support the show. 

Follow us:
Twitter 
Instagram
Linkedin
3DHEALS Website
Facebook
Facebook Group
Youtube channel

About Pitch3D 

]]> 3DHEALS Buzzsprout-16943185 Sun, 13 Apr 2025 16:00:00 -0400 5397 80 full false Episode #79 | The Orthopedic Pulse: AAOS 2025 With Matthew Henshaw Episode #79 | The Orthopedic Pulse: AAOS 2025 With Matthew Henshaw  Jenny and Matthew discussed the latest trends and innovations in the orthopedic and medical device industry, including regenerative medicine approaches for joint and spine conditions, new technologies like 3D printing and wireless endoscopes, and workflow management solutions to improve hospital efficiency after Matthew's recent blog about his AAOS 2025 experiences. They highlighted exciting startups like Genix, Osteal Therapeutics, and Ospitek that are disrupting traditional treatment paradigms. Matthew also shared his insights on the changing landscape of industry conferences and the potential impact of politics and regulation on medical innovation. Overall, the conversation covered a wide range of cutting-edge developments that could significantly improve patient outcomes and transform the future of orthopedics.

Introductions and background

Jenny and Matthew introduce themselves and provide background on their respective roles and businesses. 


Trends at recent industry conferences

Matthew shares his observations from attending recent industry conferences like the Canaccord Genuity and AAOS events. He notes trends around decreasing surgeon attendance at the larger conferences, and increased interest in regenerative medicine and solutions for prosthetic joint infections (PJI).


Regenerative medicine innovations

Matthew highlights two promising regenerative medicine companies - DiscGenics, Osteal Therapeutics, which has an implantable pain relief solution. He discusses the potential for these innovations to disrupt traditional spine surgery


Advancements in surgical tools and workflow

Matthew discusses new technologies like wireless endoscopes from companies like Lazurite and single-use endoscopes from Pristine Surgical that are improving surgical visualization and sterility. He also highlights Ospitek, a company using real-time patient tracking to optimize hospital workflow and efficiency.


Potential impact of political changes

Matthew shares his perspective on how the new Trump administration may impact medical device companies.


Recap and future outlook

Jenny and Matthew conclude by discussing the dynamic and evolving nature of the medtech industry, and the importance of remaining optimistic about the potential for innovation to improve patient outcomes, despite political and economic uncertainties.




Send us Fan Mail

Support the show

Subscribe to our premium version and support the show. 

Follow us:
Twitter 
Instagram
Linkedin
3DHEALS Website
Facebook
Facebook Group
Youtube channel

About Pitch3D 

]]>  Jenny and Matthew discussed the latest trends and innovations in the orthopedic and medical device industry, including regenerative medicine approaches for joint and spine conditions, new technologies like 3D printing and wireless endoscopes, and workflow management solutions to improve hospital efficiency after Matthew's recent blog about his AAOS 2025 experiences. They highlighted exciting startups like Genix, Osteal Therapeutics, and Ospitek that are disrupting traditional treatment paradigms. Matthew also shared his insights on the changing landscape of industry conferences and the potential impact of politics and regulation on medical innovation. Overall, the conversation covered a wide range of cutting-edge developments that could significantly improve patient outcomes and transform the future of orthopedics.

Introductions and background

Jenny and Matthew introduce themselves and provide background on their respective roles and businesses. 


Trends at recent industry conferences

Matthew shares his observations from attending recent industry conferences like the Canaccord Genuity and AAOS events. He notes trends around decreasing surgeon attendance at the larger conferences, and increased interest in regenerative medicine and solutions for prosthetic joint infections (PJI).


Regenerative medicine innovations

Matthew highlights two promising regenerative medicine companies - DiscGenics, Osteal Therapeutics, which has an implantable pain relief solution. He discusses the potential for these innovations to disrupt traditional spine surgery


Advancements in surgical tools and workflow

Matthew discusses new technologies like wireless endoscopes from companies like Lazurite and single-use endoscopes from Pristine Surgical that are improving surgical visualization and sterility. He also highlights Ospitek, a company using real-time patient tracking to optimize hospital workflow and efficiency.


Potential impact of political changes

Matthew shares his perspective on how the new Trump administration may impact medical device companies.


Recap and future outlook

Jenny and Matthew conclude by discussing the dynamic and evolving nature of the medtech industry, and the importance of remaining optimistic about the potential for innovation to improve patient outcomes, despite political and economic uncertainties.




Send us Fan Mail

Support the show

Subscribe to our premium version and support the show. 

Follow us:
Twitter 
Instagram
Linkedin
3DHEALS Website
Facebook
Facebook Group
Youtube channel

About Pitch3D 

]]> 3DHEALS Buzzsprout-16868157 Thu, 27 Mar 2025 16:00:00 -0400 4104 full false Episode #77 | Orthopedics Meets 3D Printing: A Journey Into the Future Episode #77 | Orthopedics Meets 3D Printing: A Journey Into the Future We examine the pivotal role of 3D printing technology in reshaping orthopedic implants and enhancing patient outcomes in this virtual event. This discussion navigates the crossroads of innovation and caregiving in modern medicine by featuring expert insights from industry leaders. 

• Focus on patient-specific implants and their clinical implications 
• Discussion on biocompatible materials and new technologies 
• Regulatory landscape for 3D-printed orthopedic devices 
• Insights on surgical practices and patient recovery trends 
• The benefits of personalization in surgical interventions 
• Investigations into osseointegration and design efficacy 
• Evolving market dynamics and future trends in 3D printing 

Listen to this virtual event recording, a thought-provoking exploration of 3D printing's revolution in healthcare and the impact of innovation in the orthopedic space!

Full on-demand recording: https://3dheals.com/courses/3d-printed-devices-in-orthopedics/




Send us Fan Mail

Support the show

Subscribe to our premium version and support the show. 

Follow us:
Twitter 
Instagram
Linkedin
3DHEALS Website
Facebook
Facebook Group
Youtube channel

About Pitch3D 

]]> We examine the pivotal role of 3D printing technology in reshaping orthopedic implants and enhancing patient outcomes in this virtual event. This discussion navigates the crossroads of innovation and caregiving in modern medicine by featuring expert insights from industry leaders. 

• Focus on patient-specific implants and their clinical implications 
• Discussion on biocompatible materials and new technologies 
• Regulatory landscape for 3D-printed orthopedic devices 
• Insights on surgical practices and patient recovery trends 
• The benefits of personalization in surgical interventions 
• Investigations into osseointegration and design efficacy 
• Evolving market dynamics and future trends in 3D printing 

Listen to this virtual event recording, a thought-provoking exploration of 3D printing's revolution in healthcare and the impact of innovation in the orthopedic space!

Full on-demand recording: https://3dheals.com/courses/3d-printed-devices-in-orthopedics/




Send us Fan Mail

Support the show

Subscribe to our premium version and support the show. 

Follow us:
Twitter 
Instagram
Linkedin
3DHEALS Website
Facebook
Facebook Group
Youtube channel

About Pitch3D 

]]> 3DHEALS Buzzsprout-16706534 Thu, 27 Feb 2025 18:00:00 -0500 7529 full false Episode #76 | Treating Type I Diabetes with FRESH Bioprinting: Interview with Mike Graffeo Episode #76 | Treating Type I Diabetes with FRESH Bioprinting: Interview with Mike Graffeo Discover FRESH 3D bioprinting with Mike Graffio, CEO and co-founder of Fluoform3D. Having met at Carnegie Mellon University, Mike and Adam Feinberg have been on a mission to revolutionize the field of bioprinting, focusing on creating replacement tissues and organs without introducing foreign substances into the body. Mike shares the captivating journey from their engineering days in the 1990s through a pivotal 2015 conversation that transformed their research into a thriving startup and onto achieving significant milestones like developing living cardiac tissues and heart valves by 2018.

Our conversation uncovers the next frontier in 3D bioprinting, particularly the promising strides in islet cell replacement therapy for diabetes. You'll hear about how the FRESH bioprinitng propels this innovative field forward. With breakthroughs in small animal models showing potential for diabetes management, we explore how the team is gearing up for more extensive studies and human clinical trials. This episode also delves into their strategic fundraising efforts and partnerships to bring these advancements to life.

Summary:

• Overview of Fluoform3D and its founding story 
• Explanation of FRESH Technology and its significance in bioprinting 
• Current progress in cardiac applications and in vitro tissues 
• Ongoing projects related to therapeutic applications  for type I diabetes
• Insights into navigating funding and building investor relationships 
• Discussion on regulatory pathways and interactions with the FDA 
• Emphasis on company culture and team dynamics 
• Recommendations for industry insights and staying informed about bioprinting trends

Show Notes:

Instagram interview with Mike in 2021
Fluidform3D website
Breakthrough publication in 2019 made it to the cover of Science magazine-"FRESH 3D Printing Used to Rebuild Functional Components of the Human Heart"
YouTube Video: https://youtu.be/BJbReV0v7Co

 



Send us Fan Mail

Support the show

Subscribe to our premium version and support the show. 

Follow us:
Twitter 
Instagram
Linkedin
3DHEALS Website
Facebook
Facebook Group
Youtube channel

About Pitch3D 

]]> Discover FRESH 3D bioprinting with Mike Graffio, CEO and co-founder of Fluoform3D. Having met at Carnegie Mellon University, Mike and Adam Feinberg have been on a mission to revolutionize the field of bioprinting, focusing on creating replacement tissues and organs without introducing foreign substances into the body. Mike shares the captivating journey from their engineering days in the 1990s through a pivotal 2015 conversation that transformed their research into a thriving startup and onto achieving significant milestones like developing living cardiac tissues and heart valves by 2018.

Our conversation uncovers the next frontier in 3D bioprinting, particularly the promising strides in islet cell replacement therapy for diabetes. You'll hear about how the FRESH bioprinitng propels this innovative field forward. With breakthroughs in small animal models showing potential for diabetes management, we explore how the team is gearing up for more extensive studies and human clinical trials. This episode also delves into their strategic fundraising efforts and partnerships to bring these advancements to life.

Summary:

• Overview of Fluoform3D and its founding story 
• Explanation of FRESH Technology and its significance in bioprinting 
• Current progress in cardiac applications and in vitro tissues 
• Ongoing projects related to therapeutic applications  for type I diabetes
• Insights into navigating funding and building investor relationships 
• Discussion on regulatory pathways and interactions with the FDA 
• Emphasis on company culture and team dynamics 
• Recommendations for industry insights and staying informed about bioprinting trends

Show Notes:

Instagram interview with Mike in 2021
Fluidform3D website
Breakthrough publication in 2019 made it to the cover of Science magazine-"FRESH 3D Printing Used to Rebuild Functional Components of the Human Heart"
YouTube Video: https://youtu.be/BJbReV0v7Co

 



Send us Fan Mail

Support the show

Subscribe to our premium version and support the show. 

Follow us:
Twitter 
Instagram
Linkedin
3DHEALS Website
Facebook
Facebook Group
Youtube channel

About Pitch3D 

]]> 3DHEALS Buzzsprout-16440791 Wed, 15 Jan 2025 01:00:00 -0500 2533 1 2 full false Episode #75 | #VentureCapital #Investor panel discussion for #3dprinting #startups #pitch3D #demoday Episode #75 | #VentureCapital #Investor panel discussion for #3dprinting #startups #pitch3D #demoday Our panel of investors at the 3DHEALS Pitch3D Demo Day 2025 provide 3D printing startups and entrepreneurs advice and opportunities as they start their journey in MedTech.

Nicole Black, PhD (https://www.linkedin.com/in/nicole-black-phd/) is the Program Director for MedTech Innovator, a nonprofit supporting early-stage and mid-stage medical device and diagnostics startups.

Peter Mercelis (https://www.linkedin.com/in/peter-mercelis-1624358/) is a medical device and 3D printing entrepreneur who has been active in 3D printing industry since 2003.

Dr. Jesse Courtier (https://www.linkedin.com/in/jesse-courtiermd/) is Chief of Pediatric Radiology at UCSF Benioff Children’s -San Francisco, Founder of Sira Medical, a venture backed UCSF spinout in the Augmented Reality space, and serves as an advisor to a number of accelerators and VC firms including KidsX and Avon River Ventures.

Full recordings are now on Youtube channel:

Pitch3D Playlist

Event page

Follow us: 
Twitter: https://twitter.com/3dheals
Instagram: https://www.instagram.com/3dheals/
Linkedin: https://linkedin.com/company/3dheals
Website: https://3dheals.com/
Facebook:  https://www.facebook.com/3dheals
Facebook Group: https://www.facebook.com/groups/3dheals
Youtube channel: https://www.youtube.com/@3DHEALSINNOVATION
Zoom Event Hub: https://events.zoom.us/eo/AlL-M67naa7tQL4IqXOUHjljQZI9kYu247SaGoDm-MNCWD9BuFYc~AggLXsr32QYFjq8BlYLZ5I06Dg

About Pitch3D: 
https://3dheals.com/pitch3d/

#medical3dprinting #medtech #bioimpression #surgicalplanning #ARVR #3DTechnology #anatomicalmodels #implants #digitalhealth #healthcare #biotech #bioprinting #bioprinter #tissueengineering #regenerativemedicine #biomedical #bioartificial #bioengineering  #pharma #dental3dprinting #dentallaboratory #digitaldentistry #dentistry #digitaldentures

Send us Fan Mail

Support the show

Subscribe to our premium version and support the show. 

Follow us:
Twitter 
Instagram
Linkedin
3DHEALS Website
Facebook
Facebook Group
Youtube channel

About Pitch3D 

]]> Our panel of investors at the 3DHEALS Pitch3D Demo Day 2025 provide 3D printing startups and entrepreneurs advice and opportunities as they start their journey in MedTech.

Nicole Black, PhD (https://www.linkedin.com/in/nicole-black-phd/) is the Program Director for MedTech Innovator, a nonprofit supporting early-stage and mid-stage medical device and diagnostics startups.

Peter Mercelis (https://www.linkedin.com/in/peter-mercelis-1624358/) is a medical device and 3D printing entrepreneur who has been active in 3D printing industry since 2003.

Dr. Jesse Courtier (https://www.linkedin.com/in/jesse-courtiermd/) is Chief of Pediatric Radiology at UCSF Benioff Children’s -San Francisco, Founder of Sira Medical, a venture backed UCSF spinout in the Augmented Reality space, and serves as an advisor to a number of accelerators and VC firms including KidsX and Avon River Ventures.

Full recordings are now on Youtube channel:

Pitch3D Playlist

Event page

Follow us: 
Twitter: https://twitter.com/3dheals
Instagram: https://www.instagram.com/3dheals/
Linkedin: https://linkedin.com/company/3dheals
Website: https://3dheals.com/
Facebook:  https://www.facebook.com/3dheals
Facebook Group: https://www.facebook.com/groups/3dheals
Youtube channel: https://www.youtube.com/@3DHEALSINNOVATION
Zoom Event Hub: https://events.zoom.us/eo/AlL-M67naa7tQL4IqXOUHjljQZI9kYu247SaGoDm-MNCWD9BuFYc~AggLXsr32QYFjq8BlYLZ5I06Dg

About Pitch3D: 
https://3dheals.com/pitch3d/

#medical3dprinting #medtech #bioimpression #surgicalplanning #ARVR #3DTechnology #anatomicalmodels #implants #digitalhealth #healthcare #biotech #bioprinting #bioprinter #tissueengineering #regenerativemedicine #biomedical #bioartificial #bioengineering  #pharma #dental3dprinting #dentallaboratory #digitaldentistry #dentistry #digitaldentures

Send us Fan Mail

Support the show

Subscribe to our premium version and support the show. 

Follow us:
Twitter 
Instagram
Linkedin
3DHEALS Website
Facebook
Facebook Group
Youtube channel

About Pitch3D 

]]> 3DHEALS Buzzsprout-16425869 Sun, 12 Jan 2025 21:00:00 -0500 3743 venture capital, early stage startups, biotech, medtech, 3D printing full false Episode #68 | Interview Dr. Mohit Chhaya: BellaSeno Episode #68 | Interview Dr. Mohit Chhaya: BellaSeno This just dropped! #podcast This past Saturday, I had a pleasant visit from Dr. Mohit Chhaya, CEO and co-founder of BellaSeno, a startup in Leipzig, Germany, working on #3Dprintedimplants for soft tissues and bone. We had some nice green tea and pastries and chatted about many things from his worldly experiences of residing in four countries and #GameofThrones, as well as the joy of reading. However, more importantly, we chatted about his company, technologies, vision and ambition, and a little military strategy and history. Enjoy!

Written interview here
Book suggestion: Alexander the Great and the Logistics of the Macedonian Army
Reconstruction of an Extensive Segmental Radial Shaft Bone Defect by Vascularized 3D-Printed Graft Cage




 

Send us Fan Mail

Support the show

Subscribe to our premium version and support the show. 

Follow us:
Twitter 
Instagram
Linkedin
3DHEALS Website
Facebook
Facebook Group
Youtube channel

About Pitch3D 

]]> This just dropped! #podcast This past Saturday, I had a pleasant visit from Dr. Mohit Chhaya, CEO and co-founder of BellaSeno, a startup in Leipzig, Germany, working on #3Dprintedimplants for soft tissues and bone. We had some nice green tea and pastries and chatted about many things from his worldly experiences of residing in four countries and #GameofThrones, as well as the joy of reading. However, more importantly, we chatted about his company, technologies, vision and ambition, and a little military strategy and history. Enjoy!

Written interview here
Book suggestion: Alexander the Great and the Logistics of the Macedonian Army
Reconstruction of an Extensive Segmental Radial Shaft Bone Defect by Vascularized 3D-Printed Graft Cage




 

Send us Fan Mail

Support the show

Subscribe to our premium version and support the show. 

Follow us:
Twitter 
Instagram
Linkedin
3DHEALS Website
Facebook
Facebook Group
Youtube channel

About Pitch3D 

]]> 3DHEALS Buzzsprout-15601340 Sun, 18 Aug 2024 14:00:00 -0400 4219 full false Episode #59 | IG Live with Mateusz (Matthew) Pawlik on 3D Printing Medical Devices for Animals Episode #59 | IG Live with Mateusz (Matthew) Pawlik on 3D Printing Medical Devices for Animals In this fun and insightful conversation with the co-founder and co-owner of Cabiomede (Instagram: @CabiomedeVet), I learned a lot more about Mateusz Pawlik, who is behind many of the incredible 3D printing veterinary products for both surgical plannings and for educational purposes. As a young entrepreneur, Mateusz shared with us his earlier failures right out of school, later, business pivots, and future outlook on healthcare 3D printing, not just for veterinary medicine but also for human medicine. We discussed many challenges facing the industry, in particular, how to encourage healthcare providers to adopt a new way of practice and thinking.

Links:

Instagram: https://www.instagram.com/tv/CUvBfRTJef4/?utm_source=ig_web_copy_link
Youtube:  Pending
Shownotes: https://3dheals.com/category/blog/interviews/ig-live-interview

About our guest this week:

Mateusz Pawlik, co-owner of Cabiomede

Graduate of Biomedical Engineering at the Silesian University of Technology in Poland. He gained his experience working in international companies in the medical industry as a product engineer and continuous development manager. Co-owner of CABIOMEDE – company providing R&D services in medical engineering area and Pets Analytics – startup developing an innovative solution in the field of animal health monitoring.


Operations Manager responsible for new products and technology development – presurgical models, custom made surgical guides and implants, polymeric and metal spine and joint implants for animals. Together with CABIOMEDE team developed more than 500 patient’s cases on a basis of Computed Tomography. His biggest project was related to create veterinary surgical workshop models – full canine and feline fractures database according to AOVet classification.



Send us Fan Mail

Support the show

Subscribe to our premium version and support the show. 

Follow us:
Twitter 
Instagram
Linkedin
3DHEALS Website
Facebook
Facebook Group
Youtube channel

About Pitch3D 

]]> In this fun and insightful conversation with the co-founder and co-owner of Cabiomede (Instagram: @CabiomedeVet), I learned a lot more about Mateusz Pawlik, who is behind many of the incredible 3D printing veterinary products for both surgical plannings and for educational purposes. As a young entrepreneur, Mateusz shared with us his earlier failures right out of school, later, business pivots, and future outlook on healthcare 3D printing, not just for veterinary medicine but also for human medicine. We discussed many challenges facing the industry, in particular, how to encourage healthcare providers to adopt a new way of practice and thinking.

Links:

Instagram: https://www.instagram.com/tv/CUvBfRTJef4/?utm_source=ig_web_copy_link
Youtube:  Pending
Shownotes: https://3dheals.com/category/blog/interviews/ig-live-interview

About our guest this week:

Mateusz Pawlik, co-owner of Cabiomede

Graduate of Biomedical Engineering at the Silesian University of Technology in Poland. He gained his experience working in international companies in the medical industry as a product engineer and continuous development manager. Co-owner of CABIOMEDE – company providing R&D services in medical engineering area and Pets Analytics – startup developing an innovative solution in the field of animal health monitoring.


Operations Manager responsible for new products and technology development – presurgical models, custom made surgical guides and implants, polymeric and metal spine and joint implants for animals. Together with CABIOMEDE team developed more than 500 patient’s cases on a basis of Computed Tomography. His biggest project was related to create veterinary surgical workshop models – full canine and feline fractures database according to AOVet classification.



Send us Fan Mail

Support the show

Subscribe to our premium version and support the show. 

Follow us:
Twitter 
Instagram
Linkedin
3DHEALS Website
Facebook
Facebook Group
Youtube channel

About Pitch3D 

]]> 3DHEALS Buzzsprout-9420930 Sat, 23 Oct 2021 20:00:00 -0400 2660 3D Printing for Animals, 3DVet, Veterinarian 3D Printing, 3d printing, bioprinting, Carbiomede, Pland entrepreneuers, biomedical engineering 2021 23 full false Episode #57 | Prof. Ali Khademhosseini - Academic Entrepreneur Episode #57 | Prof. Ali Khademhosseini - Academic Entrepreneur In this episode of The Lattice podcast, we had the opportunity to chat with professor Ali Khademhosseini about his career, starting when he was a chemical engineering graduate student to becoming a full professor at Harvard, bicoastal move to UCLA, three-time entrepreneur, becoming an Amazon Fellow, to finally becoming the founder and director of the Terasaki Institute, a new educational research center that also wants to build young companies. While Ali has been incredibly productive in academia, his career trajectory is clearly towards academic entrepreneurship, an exciting concept to many scientists, especially in light of the pandemic and the rise of companies like Moderna. Given his success, I dug a little deeper into his secret sauce to achieve success. Fortunately, Ali was willing to share it with everyone as well as his evolving view on what is meaningful success to him and what he envisions his next achievement milestone. Since I knew Ali from his many works on biomaterials and 3D printing, we also discussed his vision for the field.  


About our Guest for this episode: 


https://www.linkedin.com/in/alikmit/


Ali Khademhosseini is currently the CEO and Founding Director at the Terasaki Institute for Biomedical Innovation. Previously, he was a Professor of Bioengineering, Chemical Engineering and Radiology at the University of California-Los Angeles (UCLA). He joined UCLA as the Levi Knight Chair in November 2017 from Harvard University where he was Professor at Harvard Medical School (HMS) and faculty at the Harvard-MIT’s Division of Health Sciences and Technology (HST), Brigham and Women’s Hospital (BWH) and as well as associate faculty at the Wyss Institute for Biologically Inspired Engineering. At Harvard University, he directed the Biomaterials Innovation Research Center (BIRC) a leading initiative in making engineered biomedical materials. Dr. Khademhosseini is an Associate Editor for ACS Nano. He served as the Research Highlights editor for Lab on a Chip. He is a fellow of the American Institute of Medical and Biological Engineering (AIMBE), Biomedical Engineering Society (BMES), Royal Society of Chemistry (RSC), Biomaterials Science and Engineering (FBSE), Materials Research Society (MRS), NANOSMAT Society, and American Association for the Advancement of Science (AAAS). He is also the recipient of the Mustafa Prize ($500,000 prize) and is a member of the International Academy of Medical and Biological Engineering, Royal Society of Canada and Canadian Academy of Engineering, and National Academy of Inventors. He is an author on >650 peer-reviewed journal articles, editorials and review papers, >70 book chapters/edited books and >40 patents/patent applications. He has been cited >74,000 times and has an H-index of 139. He has made seminal contributions to modifying hydrogels and developing novel biomaterial solutions for addressing pressing problems in healthcare. He has founded 2 companies, Obsidio Medical and Bioray. He received his Ph.D. in bioengineering from MIT (2005), and MASc (2001) and BASc (1999) degrees from University of Toronto both in chemical engineering.



Send us Fan Mail

Support the show

Subscribe to our premium version and support the show. 

Follow us:
Twitter 
Instagram
Linkedin
3DHEALS Website
Facebook
Facebook Group
Youtube channel

About Pitch3D 

]]> In this episode of The Lattice podcast, we had the opportunity to chat with professor Ali Khademhosseini about his career, starting when he was a chemical engineering graduate student to becoming a full professor at Harvard, bicoastal move to UCLA, three-time entrepreneur, becoming an Amazon Fellow, to finally becoming the founder and director of the Terasaki Institute, a new educational research center that also wants to build young companies. While Ali has been incredibly productive in academia, his career trajectory is clearly towards academic entrepreneurship, an exciting concept to many scientists, especially in light of the pandemic and the rise of companies like Moderna. Given his success, I dug a little deeper into his secret sauce to achieve success. Fortunately, Ali was willing to share it with everyone as well as his evolving view on what is meaningful success to him and what he envisions his next achievement milestone. Since I knew Ali from his many works on biomaterials and 3D printing, we also discussed his vision for the field.  


About our Guest for this episode: 


https://www.linkedin.com/in/alikmit/


Ali Khademhosseini is currently the CEO and Founding Director at the Terasaki Institute for Biomedical Innovation. Previously, he was a Professor of Bioengineering, Chemical Engineering and Radiology at the University of California-Los Angeles (UCLA). He joined UCLA as the Levi Knight Chair in November 2017 from Harvard University where he was Professor at Harvard Medical School (HMS) and faculty at the Harvard-MIT’s Division of Health Sciences and Technology (HST), Brigham and Women’s Hospital (BWH) and as well as associate faculty at the Wyss Institute for Biologically Inspired Engineering. At Harvard University, he directed the Biomaterials Innovation Research Center (BIRC) a leading initiative in making engineered biomedical materials. Dr. Khademhosseini is an Associate Editor for ACS Nano. He served as the Research Highlights editor for Lab on a Chip. He is a fellow of the American Institute of Medical and Biological Engineering (AIMBE), Biomedical Engineering Society (BMES), Royal Society of Chemistry (RSC), Biomaterials Science and Engineering (FBSE), Materials Research Society (MRS), NANOSMAT Society, and American Association for the Advancement of Science (AAAS). He is also the recipient of the Mustafa Prize ($500,000 prize) and is a member of the International Academy of Medical and Biological Engineering, Royal Society of Canada and Canadian Academy of Engineering, and National Academy of Inventors. He is an author on >650 peer-reviewed journal articles, editorials and review papers, >70 book chapters/edited books and >40 patents/patent applications. He has been cited >74,000 times and has an H-index of 139. He has made seminal contributions to modifying hydrogels and developing novel biomaterial solutions for addressing pressing problems in healthcare. He has founded 2 companies, Obsidio Medical and Bioray. He received his Ph.D. in bioengineering from MIT (2005), and MASc (2001) and BASc (1999) degrees from University of Toronto both in chemical engineering.



Send us Fan Mail

Support the show

Subscribe to our premium version and support the show. 

Follow us:
Twitter 
Instagram
Linkedin
3DHEALS Website
Facebook
Facebook Group
Youtube channel

About Pitch3D 

]]> 3DHEALS Buzzsprout-9283777 Wed, 29 Sep 2021 20:00:00 -0400 1996 3D Printing, Bob Langer, MIT, Harvard, UCLA, Terasaki Institute 2021 21 full false Episode #33 | Fireside Chat with Tamer Mohamed (Aspect Biosystems) and Mike Graffeo (Fluidform) Episode #33 | Fireside Chat with Tamer Mohamed (Aspect Biosystems) and Mike Graffeo (Fluidform) A fun but insightful conversation during 3DHEALS2020 with two inspiring entrepreneurs in 3D Bioprinting space, Tamer Mohamed (CEO and co-founder of Aspect Biosystems), and Mike Graffeo (CEO and co-founder of Fluidform). Aspect bio has just successfully completed its series A round, and Fluidform just successfully raised its seed round. Learn from Tamer and Mike on what startup CEOs' challenges, experiences, visions, and advice for the biofabrication and 3D printing space.

Full conference video recording can be purchased here. 

Send us Fan Mail

Support the show

Subscribe to our premium version and support the show. 

Follow us:
Twitter 
Instagram
Linkedin
3DHEALS Website
Facebook
Facebook Group
Youtube channel

About Pitch3D 

]]> A fun but insightful conversation during 3DHEALS2020 with two inspiring entrepreneurs in 3D Bioprinting space, Tamer Mohamed (CEO and co-founder of Aspect Biosystems), and Mike Graffeo (CEO and co-founder of Fluidform). Aspect bio has just successfully completed its series A round, and Fluidform just successfully raised its seed round. Learn from Tamer and Mike on what startup CEOs' challenges, experiences, visions, and advice for the biofabrication and 3D printing space.

Full conference video recording can be purchased here. 

Send us Fan Mail

Support the show

Subscribe to our premium version and support the show. 

Follow us:
Twitter 
Instagram
Linkedin
3DHEALS Website
Facebook
Facebook Group
Youtube channel

About Pitch3D 

]]> Tamer Mohamed/Mike Graffeo Buzzsprout-4122611 Wed, 10 Jun 2020 17:00:00 -0400 1732 3DHEALS2020, Entreprenuership, Bioprinting, 3D printing full false Episode #31 | Orthopedic Surgery in the Era of Industry 4.0 - An Interview with Carlsmed CEO Mike Cordonnier Episode #31 | Orthopedic Surgery in the Era of Industry 4.0 - An Interview with Carlsmed CEO Mike Cordonnier Have a complex spine problem? Mike Cordonnier from Carlsmed may have an answer for you. While orthopedic surgeons are no strangers to virtual pre-operative surgical planning, it is a different challenge to also provide a patient-specific implant to fit into the patient, rather than molding patient to fit the device. In this interview with our upcoming 3DHEALS2020 speaker, Mike and I discussed how his company aims to realize medical imaging to patient-specific surgical plan and device, leveraging AI, cloud computing, data, and additive manufacturing (or 3D printing). We also touched upon how the ongoing COVID19 pandemic will change the future of surgery. 


Mike Cordonnier is CEO and co-founder of Carlsmed, a San Diego based Med Tech company. Carlsmed’s Corra system utilizes predictive analytics to create patient-specific surgical plans and 3d printed implants to improve patient outcomes for spine surgery.  Mike has held various leadership roles for large MedTech companies NuVasive, Zimmer Biomet, and Orchid Orthopedics as well as early-stage startups Ellipse Technologies and X-Spine Systems.  Mike is passionate about leveraging technology to improve patient outcomes and decrease the cost of healthcare.  Mike has a B.S. in Mechanical Engineering from the University of Dayton. Mike will be a speaker for 3DHEALS2020 Orthopedic Panel.

Send us Fan Mail

Support the show

Subscribe to our premium version and support the show. 

Follow us:
Twitter 
Instagram
Linkedin
3DHEALS Website
Facebook
Facebook Group
Youtube channel

About Pitch3D 

]]> Have a complex spine problem? Mike Cordonnier from Carlsmed may have an answer for you. While orthopedic surgeons are no strangers to virtual pre-operative surgical planning, it is a different challenge to also provide a patient-specific implant to fit into the patient, rather than molding patient to fit the device. In this interview with our upcoming 3DHEALS2020 speaker, Mike and I discussed how his company aims to realize medical imaging to patient-specific surgical plan and device, leveraging AI, cloud computing, data, and additive manufacturing (or 3D printing). We also touched upon how the ongoing COVID19 pandemic will change the future of surgery. 


Mike Cordonnier is CEO and co-founder of Carlsmed, a San Diego based Med Tech company. Carlsmed’s Corra system utilizes predictive analytics to create patient-specific surgical plans and 3d printed implants to improve patient outcomes for spine surgery.  Mike has held various leadership roles for large MedTech companies NuVasive, Zimmer Biomet, and Orchid Orthopedics as well as early-stage startups Ellipse Technologies and X-Spine Systems.  Mike is passionate about leveraging technology to improve patient outcomes and decrease the cost of healthcare.  Mike has a B.S. in Mechanical Engineering from the University of Dayton. Mike will be a speaker for 3DHEALS2020 Orthopedic Panel.

Send us Fan Mail

Support the show

Subscribe to our premium version and support the show. 

Follow us:
Twitter 
Instagram
Linkedin
3DHEALS Website
Facebook
Facebook Group
Youtube channel

About Pitch3D 

]]> Mike Cordonnier, CEO Carlsmed Buzzsprout-3898949 Sun, 24 May 2020 18:00:00 -0400 1103 orthopedic 3D printing, metal 3D printing, 3DHEALS2020, Carlsmed full false Episode #28 | Interview with Dr. Shafkat Anwar, Pediatric Cardiologist & Director of Center of 3D Technologies, UCSF Episode #28 | Interview with Dr. Shafkat Anwar, Pediatric Cardiologist & Director of Center of 3D Technologies, UCSF A lot of us started our journey in healthcare 3D printing accidentally. Listen to this ice-breaker style interview with Dr. Shafkat Anwar, Pediatric Cardiology Director of Cardiac MRI, as well as Co-Founder and Co-Director of the UCSF Center for Advanced 3D+ Technologies (CA3D+). Hear his story on how 3D+ Technologies beyond 3D printing is helping patients (and their families) fighting against congenital heart disease and how UCSF 3D+ Lab is combating against the ongoing pandemic. His full written interview can be found here.   He will be speaking at "Point of Care" panel at the upcoming 3DHEALS2020 in June, 2020.


Dr. Shafkat Anwar (Twitter: @ShafkatAnwar) is a pediatric cardiologist with a specialty in non-invasive cardiac imaging, including echocardiography and cardiac magnetic resonance imaging (MRI). 

He is the Pediatric Cardiology Director of Cardiac MRI, as well as Co-Founder and Co-Director of the UCSF Center for Advanced 3D+ Technologies (CA3D+). He is a founding member and the inaugural Chair of the Advanced 3D+ Visualization Special Interest Group in the Society for Cardiovascular Magnetic Resonance. He is a consultant at Printerprezz, a medical start-up in Fremont, CA utilizing additive and other advanced manufacturing technologies to develop the next generation of medical devices.  At Printerprezz. Dr. Anwar serves as the Senior Vice President of Medical Innovations. Dr. Anwar completed his internship and residency in Pediatrics at Children’s National Medical Center, as well as a research fellowship at the National Institutes of Health. He completed fellowships in Pediatric Cardiology and Cardiac Imaging at Cleveland Clinic and Children’s Hospital of Philadelphia. Prior to joining UCSF, Dr. Anwar was the Cardiology Director of Cardiac MRI at Washington University in St. Louis, St. Louis Children’s Hospital.  At Wash. U. Dr. Anwar co-founded and co-directed the Center for 3D Printing, a multi-disciplinary 3D printing center. He will be speaking at "Point of Care" panel at the upcoming 3DHEALS2020 in June, 2020.

Send us Fan Mail

Support the show

Subscribe to our premium version and support the show. 

Follow us:
Twitter 
Instagram
Linkedin
3DHEALS Website
Facebook
Facebook Group
Youtube channel

About Pitch3D 

]]> A lot of us started our journey in healthcare 3D printing accidentally. Listen to this ice-breaker style interview with Dr. Shafkat Anwar, Pediatric Cardiology Director of Cardiac MRI, as well as Co-Founder and Co-Director of the UCSF Center for Advanced 3D+ Technologies (CA3D+). Hear his story on how 3D+ Technologies beyond 3D printing is helping patients (and their families) fighting against congenital heart disease and how UCSF 3D+ Lab is combating against the ongoing pandemic. His full written interview can be found here.   He will be speaking at "Point of Care" panel at the upcoming 3DHEALS2020 in June, 2020.


Dr. Shafkat Anwar (Twitter: @ShafkatAnwar) is a pediatric cardiologist with a specialty in non-invasive cardiac imaging, including echocardiography and cardiac magnetic resonance imaging (MRI). 

He is the Pediatric Cardiology Director of Cardiac MRI, as well as Co-Founder and Co-Director of the UCSF Center for Advanced 3D+ Technologies (CA3D+). He is a founding member and the inaugural Chair of the Advanced 3D+ Visualization Special Interest Group in the Society for Cardiovascular Magnetic Resonance. He is a consultant at Printerprezz, a medical start-up in Fremont, CA utilizing additive and other advanced manufacturing technologies to develop the next generation of medical devices.  At Printerprezz. Dr. Anwar serves as the Senior Vice President of Medical Innovations. Dr. Anwar completed his internship and residency in Pediatrics at Children’s National Medical Center, as well as a research fellowship at the National Institutes of Health. He completed fellowships in Pediatric Cardiology and Cardiac Imaging at Cleveland Clinic and Children’s Hospital of Philadelphia. Prior to joining UCSF, Dr. Anwar was the Cardiology Director of Cardiac MRI at Washington University in St. Louis, St. Louis Children’s Hospital.  At Wash. U. Dr. Anwar co-founded and co-directed the Center for 3D Printing, a multi-disciplinary 3D printing center. He will be speaking at "Point of Care" panel at the upcoming 3DHEALS2020 in June, 2020.

Send us Fan Mail

Support the show

Subscribe to our premium version and support the show. 

Follow us:
Twitter 
Instagram
Linkedin
3DHEALS Website
Facebook
Facebook Group
Youtube channel

About Pitch3D 

]]> Dr. Shafkat Anwar/UCSF Buzzsprout-3750566 Thu, 14 May 2020 02:00:00 -0400 1142 3DHEALS2020, cardiac imaging, 3D Printing for Congenital Heart Disease, Point of Care for 3D Printing full false Episode #16 | Interview with 3DHEALS2020 Speaker, Kevin Caldwell, CEO of Ossium Health Episode #16 | Interview with 3DHEALS2020 Speaker, Kevin Caldwell, CEO of Ossium Health Join me for a fascinating conversation with 3DHEALS2020 speaker, Kevin Caldwell, CEO and co-founder of Ossium Health, a startup building a bone marrow bank, and providing solutions to more available bone marrow transplant and other related cell therapies. Learn more about Kevin's personal journey as an entrepreneur, how such a bone marrow/stem cell band from organ donors can help biofabrication and tissue engineering, and the bioethical concerns with cell therapy and tissue engineering. The video version of this interview can be found here. Stay tuned for more in-depth written interview with Kevin at 3DHEALS.com.

Guest Biography: 

Kevin E. Caldwell II is the Co-founder, President & CEO of Ossium  Health, where he leads a team that is building the world’s first bone marrow bank. Kevin previously worked in consulting as an Engagement Manager at leading strategy consulting firm 
McKinsey. Prior to that, he served in the Quantitative Research department of the hedge fund Bridgewater Associates. Kevin was trained in Physics and Economics at MIT before receiving his JD from Harvard Law School.

Send us Fan Mail

Support the show

Subscribe to our premium version and support the show. 

Follow us:
Twitter 
Instagram
Linkedin
3DHEALS Website
Facebook
Facebook Group
Youtube channel

About Pitch3D 

]]> Join me for a fascinating conversation with 3DHEALS2020 speaker, Kevin Caldwell, CEO and co-founder of Ossium Health, a startup building a bone marrow bank, and providing solutions to more available bone marrow transplant and other related cell therapies. Learn more about Kevin's personal journey as an entrepreneur, how such a bone marrow/stem cell band from organ donors can help biofabrication and tissue engineering, and the bioethical concerns with cell therapy and tissue engineering. The video version of this interview can be found here. Stay tuned for more in-depth written interview with Kevin at 3DHEALS.com.

Guest Biography: 

Kevin E. Caldwell II is the Co-founder, President & CEO of Ossium  Health, where he leads a team that is building the world’s first bone marrow bank. Kevin previously worked in consulting as an Engagement Manager at leading strategy consulting firm 
McKinsey. Prior to that, he served in the Quantitative Research department of the hedge fund Bridgewater Associates. Kevin was trained in Physics and Economics at MIT before receiving his JD from Harvard Law School.

Send us Fan Mail

Support the show

Subscribe to our premium version and support the show. 

Follow us:
Twitter 
Instagram
Linkedin
3DHEALS Website
Facebook
Facebook Group
Youtube channel

About Pitch3D 

]]> Kevin Caldwell/ Ossium Health Buzzsprout-3545374 Tue, 28 Apr 2020 17:00:00 -0400 1444 Ossium Health, bone marrow bank, biofabrication, 3DHEALS2020, bioprinting, cell therapy full false